GLP-1 Market
LLY $1137.82 ▲ +0.2% NVO $41.71 ▼ -1.9% PFE $27.46 ▼ -0.3% VKTX $29.52 ▼ -1.4% KLRA $12.70 ▼ -5.6% GPCR $35.50 ▼ -8.9% RHHBY $55.15 ▲ +0.4%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Fludarabine Phosphate

Company
St. Jude Children's Research Hospital
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
117 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

117 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Sep 17, 2026

Find a Clinical Trial Near Me

See recruiting studies for Fludarabine Phosphate and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT01804634

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 60 participants Est. completion 2030-01 3 sites Stand-alone
    Other conditions: Refractory and/or Relapsed Metastatic Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT01949129

    Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

    Not yet reported, Not yet reported St. Anna Kinderkrebsforschung 1800 participants Est. completion 2030-06-01 119 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukaemia
    View official trial listing →
  • Recruiting NCT NCT02133196

    T Cell Receptor Immunotherapy for Patients With Metastatic Non-Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 85 participants Est. completion 2027-10-23 1 site Stand-alone
    Other conditions: Advanced Non-Small Cell Lung Cancer, Squamous Cell Carcinoma, Advanced NSCLC, Adenosquamous Carcinoma, Adenocarcinoma
    View official trial listing →
  • Recruiting NCT NCT02508038

    Alpha/Beta CD19+ Depleted Haploidentical Transplantation + Zometa for Pediatric Hematologic Malignancies and Solid Tumors

    Not yet reported University of Wisconsin, Madison 22 participants Est. completion 2027-12 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, Myelodysplastic Syndrome, Myeloproliferative Syndrome, Ewing Sarcoma, Primitive Neuroectodermal Tumor, Neuroblastoma
    View official trial listing →
  • Recruiting NCT NCT02621021

    A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab

    Not yet reported National Cancer Institute (NCI) 53 participants Est. completion 2029-06-16 1 site Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Recruiting NCT NCT02917083

    CD30 CAR T Cells, Relapsed CD30 Expressing Lymphoma (RELY-30)

    Not yet reported Baylor College of Medicine 60 participants Est. completion 2040-02 2 sites Stand-alone
    Other conditions: Hodgkin's Lymphoma, Non-Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT03128996

    Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

    Not yet reported, Not yet reported Washington University School of Medicine 29 participants Est. completion 2033-04 4 sites Stand-alone
    Other conditions: Severe Sickle Cell Disease, Bone Marrow Failure Syndromes, Metabolic Disorders, Immunologic Disorders, Hemoglobinopathies, Non-malignant Disorders
    View official trial listing →
  • Recruiting NCT NCT03721068

    Study of CAR T-Cells Targeting the GD2 With IL-15+iCaspase9 for Relapsed/Refractory Neuroblastoma or Relapsed/Refractory Osteosarcoma

    Not yet reported UNC Lineberger Comprehensive Cancer Center 18 participants Est. completion 2044-06-19 2 sites Stand-alone
    Obstructive sleep apnea Other conditions: Neuroblastoma
    View official trial listing →
  • Recruiting NCT NCT03937544

    Intravenous Autologous CD19 CAR-T Cells for R/R B-ALL

    Not yet reported, Not yet reported National University of Malaysia 10 participants Est. completion 2027-03-18 1 site Stand-alone
    Other conditions: Relapsed B Acute Lymphoblastic Leukaemia, Refractory B Acute Lymphoblastic Leukaemia
    View official trial listing →
  • Recruiting NCT NCT03964506

    Hyperbaric Oxygen Therapy and Allogeneic Peripheral Blood Stem Cell (PBSC) Transplant

    Not yet reported Omar Aljitawi 24 participants Est. completion 2028-03-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Atypical Chronic Myeloid Leukemia, Chronic Monocytic Leukemia, Myelofibrosis, Myelodysplastic/Myeloproliferative Neoplasm
    View official trial listing →
  • Recruiting NCT NCT03970096

    Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)

    Not yet reported Fred Hutchinson Cancer Center 120 participants Est. completion 2029-12-31 3 sites Stand-alone
    Other conditions: Acute Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
    View official trial listing →
  • Recruiting NCT NCT04083183

    Total Body Irradiation and Astatine-211-Labeled BC8-B10 Monoclonal Antibody for the Treatment of Nonmalignant Diseases

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 40 participants Est. completion 2028-01-09 1 site Stand-alone
    Other conditions: Non-Malignant Neoplasm
    View official trial listing →
  • Recruiting NCT NCT04232085

    Regenerative Medicine to Restore Hematopoiesis and Immune Function in Immunodeficiencies and Inherited Bone Marrow Failures

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 27 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: Primary Immune Deficiency Disorder, Immune Deficiency Disease, Bone Marrow Failure, Short Telomere Length, Fanconi Anemia, Non Fanconi DNA-DSB Repair Disorder, Hoyeraal-Hreidarsson Syndrome, Dyskeratosis Congenita, Telomere Biology Disorder, Short Telomere Syndrome
    View official trial listing →
  • Recruiting NCT NCT04339777

    Allogeneic Hematopoietic Stem Cell Transplant for Patients With Inborn Errors of Immunity

    Not yet reported National Cancer Institute (NCI) 66 participants Est. completion 2027-11-30 1 site
    Other conditions: Lymphoproliferative Disorders, Autoimmune Lymphoproliferative, Immune System Diseases, Common Variable Immunodeficiency, Primary T-cell Immunodeficiency Disorders
    View official trial listing →
  • Recruiting NCT NCT04558736

    Haploidentical HCT for Severe Aplastic Anemia

    Not yet reported St. Jude Children's Research Hospital 21 participants Est. completion 2030-07-01 1 site Stand-alone
    Other conditions: Aplastic Anemia, Bone Marrow Failure Syndrome
    View official trial listing →
  • Recruiting NCT NCT04708054

    Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 324 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Recruiting NCT NCT04784052

    Depleted Donor Stem Cell Transplant in Children and Adults With Fanconi Anemia After Being Conditioned With a Regimen Containing Briquilimab

    Not yet reported, Not yet reported Porteus, Matthew, MD 18 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Fanconi Anemia
    View official trial listing →
  • Recruiting NCT NCT04815356

    Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

    Not yet reported National Cancer Institute (NCI) 27 participants Est. completion 2036-12-01 1 site Stand-alone
    Other conditions: Hairy Cell Leukemia, Hairy Cell Leukemia Variant
    View official trial listing →
  • Recruiting NCT NCT04848064

    Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma

    Not yet reported John Reneau 12 participants Est. completion 2027-01-30 1 site Stand-alone
    Other conditions: Recurrent Adult T-Cell Leukemia/Lymphoma, Recurrent Primary Cutaneous T-Cell Non-Hodgkin Lymphoma, Refractory Adult T-Cell Leukemia/Lymphoma, Refractory Primary Cutaneous T-Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05010564

    Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

    Not yet reported Baylor College of Medicine 38 participants Est. completion 2040-03-29 1 site Stand-alone
    Other conditions: Leukemia, B-Cell
    View official trial listing →
  • Recruiting NCT NCT05092451

    Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapse/Refractory Hematological Malignances

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 80 participants Est. completion 2030-08-31 1 site Stand-alone
    Other conditions: B-Cell Lymphoma, Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML), Multiple Myeloma, Plasma Cell Leukemia, Hodgkin Lymphoma, T-cell Non-Hodgkin's Lymphoma/ T-cell Acute Lymphoblastic Leukmeia, Myelodysplastic Syndrome / Chronic Myelomonocytic Leukemia, Blastic Transformation of Chronic Myeloid Leukemia, Germ Cell Tumors
    View official trial listing →
  • Recruiting NCT NCT05310591

    Combination of an Anti-PD1 Antibody With Tisagenlecleucel Reinfusion in Children, Adolescents and Young Adults With Acute Lymphoblastic Leukemia After Loss of Persistence

    Not yet reported, Not yet reported Assistance Publique - Hôpitaux de Paris 26 participants Est. completion 2027-03 13 sites Stand-alone
    Other conditions: B Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia, in Relapse
    View official trial listing →
  • Recruiting NCT NCT05326243

    Phase 1/2 Study of CD19 Chimeric Antigen Receptor T-cell (CD19 CAR-T; PL001) for Relapsed or Refractory B-cell Lymphoma

    Not yet reported, Not yet reported Pell Bio-Med Technology Co., Ltd. 49 participants Est. completion 2027-03-31 5 sites Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Large B-cell Lymphoma, Follicular Lymphoma Grade 3A, Follicular Lymphoma Grade 3B
    View official trial listing →
  • Recruiting NCT NCT05334823

    A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents

    Not yet reported Chongqing Precision Biotech Co., Ltd 100 participants Est. completion 2029-07-01 16 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT05426252

    Thal-Fabs: Reduced Toxicity Conditioning for High Risk Thalassemia

    Not yet reported, Not yet reported The Hospital for Sick Children 20 participants Est. completion 2026-12-31 1 site
    Other conditions: Thalassemia in Children
    View official trial listing →
  • Recruiting NCT NCT05427136

    Early Pulmonary Dysfunction in Childhood Cancer Patients

    University Children's Hospital Basel 140 participants Est. completion 2051-06 5 sites
    Other conditions: Pulmonary Dysfunction
    View official trial listing →
  • Recruiting NCT NCT05445011

    Anti-FLT3 CAR-T Cell (TAA05 Cell Injection) in the Treatment of Relapsed / Refractory Acute Myeloid Leukemia

    Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 12 participants Est. completion 2027-06-14 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT05586074

    HEC73543 Versus Salvage Chemotherapy in R/R FLT3-ITD AML

    Not yet reported Sunshine Lake Pharma Co., Ltd. 324 participants Est. completion 2028-05-30 1 site
    Other conditions: Leukemia, Acute Myeloid (AML)
    View official trial listing →
  • Recruiting NCT NCT05625594

    Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tn/Mem T-lymphocytes) for the Treatment of Central Nervous System Lymphoma

    Not yet reported City of Hope Medical Center 20 participants Est. completion 2028-05-22 1 site Stand-alone
    Other conditions: Central Nervous System Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05639972

    E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

    Not yet reported, Not yet reported Christian Hinrichs 15 participants Est. completion 2026-10-01 2 sites Stand-alone
    Other conditions: HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, HPV-Related Malignancy, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV-Related Endocervical Adenocarcinoma, Cervical Cancer, Oropharynx Cancer, Anal Cancer, Vulvar Cancer, Penile Cancer, Vaginal Cancer
    View official trial listing →
  • Recruiting NCT NCT05667506

    A Study of CNCT19 Treatment in Children and Adolescent r/r ALL Patients(Pediatric)

    Not yet reported, Not yet reported Juventas Cell Therapy Ltd. 47 participants Est. completion 2027-05-30 9 sites Stand-alone
    Other conditions: B-cell Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT05686226

    E7 TCR-T Cell Immunotherapy for Human Papillomavirus (HPV) Associated Cancers

    Not yet reported Christian Hinrichs 20 participants Est. completion 2027-01-01 3 sites Stand-alone
    Other conditions: Cervical Cancer, Throat Cancer, Oropharynx Cancer, Anal Cancer, Vulva Cancer, Vaginal Cancer, Penile Cancer, Metastatic Cancer, HPV-Related Malignancy, HPV-Related Carcinoma, HPV-Related Cervical Carcinoma, HPV-Related Squamous Cell Carcinoma, HPV-Related Adenocarcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Associated Vaginal Adenocarcinoma, HPV-Related Adenosquamous Carcinoma, HPV-Related Endocervical Adenocarcinoma, HPV-Related Anal Squamous Cell Carcinoma, HPV-Related Penile Squamous Cell Carcinoma, HPV-Related Vulvar Squamous Cell Carcinoma, HPV Positive Rectal Squamous Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT05735717

    MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

    Not yet reported Masonic Cancer Center, University of Minnesota 70 participants Est. completion 2030-11-30 1 site Stand-alone
    Other conditions: Hematologic Malignancy, Acute Leukemia, Remission, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, AML, TP53, Intrachromosomal Amplification of Chromosome 21, Cytogenetic Abnormality, CNS Leukemia, Minimal Residual Disease, Myelodysplasia, Juvenile Myelomonocytic Leukemia, Somatic Mutation, PTPN11 Gene Mutation, N-RAS Gene Amplification, Neurofibromatosis 1, NF1 Mutation, CBL Gene Mutation, Monosomy 7, Chromosome Abnormality, Fetal Hemoglobin, Lymphoblastic Lymphoma, High Grade Non-Hodgkin's Lymphoma, Adult
    View official trial listing →
  • Recruiting NCT NCT05768529

    Clinical Study of U16 in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

    Not yet reported, Not yet reported Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 100 participants Est. completion 2026-12-31 2 sites Stand-alone
    Other conditions: Relapsed or Refractory Non-Hodgkin's Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05849662

    A Phase I/II Study of Trametinib and Azacitidine for Patients With Newly Diagnosed Juvenile Myelomonocytic Leukemia

    Not yet reported, Not yet reported Therapeutic Advances in Childhood Leukemia Consortium 58 participants Est. completion 2029-12 21 sites Stand-alone
    Other conditions: Leukemia, Juvenile Myelomonocytic, JMML, JCML, Neurofibromatosis 1, CBL Syndrome
    View official trial listing →
  • Recruiting NCT NCT05877599

    A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

    Not yet reported AstraZeneca 45 participants Est. completion 2029-07-31 23 sites Stand-alone
    Other conditions: Non-small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Colorectal Carcinoma, Pancreatic Adenocarcinoma, Breast Cancer, Other Solid Tumors, Ovarian Cancer, Myeloid Neoplasms (AML/MDS)
    View official trial listing →
  • Recruiting NCT NCT05913804

    YTS104 Cell Injection for the Treatment of Relapsed or Refractory Multiple Myeloma

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 12 participants Est. completion 2025-12-30 1 site Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05949125

    Phase 1 Study of Allo-RevCAR01-T-CD123 in Patients With Selected CD123 Positive Hematologic Malignancies

    Not yet reported AvenCell Europe GmbH 80 participants Est. completion 2028-01 11 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
    View official trial listing →
  • Recruiting NCT NCT05952947

    HRYZ-T101 Injection for HPV18 Positive Solid Tumor

    Not yet reported HRYZ Biotech Co. 32 participants Est. completion 2028-02 1 site Stand-alone
    Other conditions: Cervical Cancer, Head and Neck Squamous Cell Carcinoma, Carcinoma of Vagina, Carcinoma of Penis, Anal Cancer, Carcinoma of Vulva
    View official trial listing →
  • Recruiting NCT NCT05963217

    Study of TBI-2001(Autologous CD19 Specific Chimeric Antigen Receptor (CAR) Gene-transduced T Lymphocytes) for Relapsed or Refractory CD19+ B-cell Lymphoma, CLL/SLL

    Not yet reported University Health Network, Toronto 19 participants Est. completion 2028-06-30 1 site Stand-alone
    Other conditions: Relapsed or Refractory CD19+ B-cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05981014

    Study of Autologous Tumor-Draining Lymph Node-Derived Lymphocytes as Neoadjuvant Therapy for HER2-Negative Breast Cancer

    Not yet reported, Not yet reported Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University 196 participants Est. completion 2035-05-31 1 site Stand-alone
    Other conditions: Breast Neoplasms
    View official trial listing →
  • Recruiting NCT NCT05991908

    Randomized Study of Conditioning of Fludarabine Combined With Single or Dual Alkylating Agents in Myeloid Malignancies

    Not yet reported Shanghai Jiao Tong University School of Medicine 222 participants Est. completion 2026-06-30 9 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Recruiting NCT NCT06013423

    Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases

    Not yet reported Fred Hutchinson Cancer Center 54 participants Est. completion 2032-10-31 1 site Stand-alone
    Other conditions: Acute Leukemia of Ambiguous Lineage, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Blastic Plasmacytoid Dendritic Cell Neoplasm, Hematopoietic and Lymphatic System Neoplasm, Mixed Phenotype Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Chronic Myeloid Leukemia, BCR-ABL1 Positive
    View official trial listing →
  • Recruiting NCT NCT06026319

    CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

    Not yet reported Marcela V. Maus, M.D.,Ph.D. 24 participants Est. completion 2028-01-01 1 site Stand-alone
    Other conditions: Non-hodgkin Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma (PMBCL), High-grade B-cell Lymphoma, Grade 3b Follicular Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06028828

    Risk-ADAPTed Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation

    Not yet reported University of California, Irvine 60 participants Est. completion 2027-09 1 site Stand-alone
    Other conditions: Allogeneic Hematopoietic Stem Cell Transplantation, Allogeneic Stem Cell Transplantation, Hematologic Malignancies
    View official trial listing →
  • Recruiting NCT NCT06083883

    Phase I/Ib Study of NK Expressing an Affinity-enhanced T-cell Receptor (TCR) Against the NY-ESO-1

    Not yet reported M.D. Anderson Cancer Center 44 participants Est. completion 2028-11-30 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Synovial Sarcoma
    View official trial listing →
  • Recruiting NCT NCT06153251

    A Study to Assess BMS-986453 in Participants With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 187 participants Est. completion 2030-05-02 19 sites Stand-alone
    Other conditions: Relapsed and/or Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06173518

    A Study of CD19 Targeted CAR T Cell Therapy in Pediatric Patients With Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia (B ALL) and Aggressive Mature B-cell Non-Hodgkin Lymphoma (B NHL)

    Not yet reported Autolus Limited 30 participants Est. completion 2027-11 9 sites Stand-alone
    Other conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia, Relapsed or Refractory B Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06191887

    B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic Malignancies

    Not yet reported Mayo Clinic 27 participants Est. completion 2040-12-31 1 site Stand-alone
    Other conditions: B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Small Lymphocytic Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06193486

    Autologous Gamma Delta T Cells to Target Prostate Stem Cell Antigen in mCRPC

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 30 participants Est. completion 2033-12-13 1 site Stand-alone
    Other conditions: Metastatic Castration-resistant Prostate Cancer
    View official trial listing →
  • Recruiting NCT NCT06199427

    PTCy and and Ruxolitinib for GVHD Prophylaxis After HSCT With Thymoglobulin in Conditioning Regimen in Patients With Inborn Errors of Immunity

    Not yet reported Federal Research Institute of Pediatric Hematology, Oncology and Immunology 100 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Inborn Errors of Immunity
    View official trial listing →
  • Recruiting NCT NCT06215950

    A Clinical Research About CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Gynecologic Cancer

    Not yet reported Chongqing Precision Biotech Co., Ltd 36 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Ovarian Cancer, Cervix Cancer, Metastatic Cancer, Advanced Cancer, Gynecologic Cancer
    View official trial listing →
  • Recruiting NCT NCT06252870

    Study Testing Two Conditioning Regimen With a Single Prophylaxis of GVHD by Cyclophosphamide and Methotrexate Post-transplant in Patients Eligible for Matched-donor Allograft Transplantation

    Not yet reported Nantes University Hospital 82 participants Est. completion 2028-07-18 3 sites Stand-alone
    Other conditions: Graft Versus Host Disease, Hematologic Malignancy
    View official trial listing →
  • Recruiting NCT NCT06262438

    CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients

    Not yet reported Princess Maxima Center for Pediatric Oncology 60 participants Est. completion 2032-06 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia in Children
    View official trial listing →
  • Recruiting NCT NCT06265584

    Trial of 2 Step ATG for Prevention of Acute GVHD Post Allogeneic Stem Cell Transplant

    Not yet reported University of Alabama at Birmingham 56 participants Est. completion 2028-11 1 site Stand-alone
    Other conditions: Acute Leukemia, Myelodysplastic Syndrome, Myeloproliferative Disorders
    View official trial listing →
  • Recruiting NCT NCT06321289

    Allogeneic TRAC Locus-inserted CD19-targeting STAR T Cell Therapy in r/r B-NHL

    Not yet reported, Not yet reported Chinese PLA General Hospital 30 participants Est. completion 2027-03-20 2 sites Stand-alone
    Other conditions: Non-hodgkin Lymphoma,B Cell
    View official trial listing →
  • Recruiting NCT NCT06323525

    TCR Reserved and Power3 (SPPL3) Gene Knock-out Allogeneic CD19-targeting CAR-T Cell Therapy in r/r B Cell Lymphoma

    Not yet reported, Not yet reported Chinese PLA General Hospital 30 participants Est. completion 2027-04-25 3 sites Stand-alone
    Other conditions: Non-hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06345495

    High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly

    Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2029-01-01 1 site Stand-alone
    Other conditions: Splenomegaly, Myelofibrosis
    View official trial listing →
  • Recruiting NCT NCT06387069

    A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia

    Not yet reported Hutchmed 316 participants Est. completion 2029-09-30 53 sites
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06395870

    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported Tianjin Medical University Cancer Institute and Hospital 33 participants Est. completion 2028-06-30 2 sites Stand-alone
    Other conditions: B-Cell Non-Hodgkin Lymphoma-Recurrent, B-Cell Non-Hodgkin Lymphoma-Refractory
    View official trial listing →
  • Recruiting NCT NCT06412497

    MT2023-20: Hematopoietic Cell Transplant With Reduced Intensity Conditioning and Post-transplant Cyclophosphamide for Severe Aplastic Anemia and Other Forms of Acquired Bone Marrow Failure.

    Not yet reported Masonic Cancer Center, University of Minnesota 60 participants Est. completion 2036-05-01 1 site Stand-alone
    Other conditions: Severe Aplastic Anemia, Acquired Amegakaryocytic Thrombocytopenia, Acquired Pure Red Cell Aplasia, Paroxysmal Nocturnal Hemoglobinuria
    View official trial listing →
  • Recruiting NCT NCT06420063

    Sequential CAR-T Cells Targeting CD33/CD123 in Patients With Acute Myelocytic Leukemia AML

    Not yet reported, Not yet reported Essen Biotech 85 participants Est. completion 2026-12-28 1 site Stand-alone
    Other conditions: AML, Acute Myeloid Leukemia, AML, Adult Recurrent, AML, Adult
    View official trial listing →
  • Recruiting NCT NCT06420076

    Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells

    Not yet reported, Not yet reported Essen Biotech 60 participants Est. completion 2026-12-28 1 site Stand-alone
    Other conditions: T Cell Lymphoma, T Cell Leukemia, T-cell Acute Lymphoblastic Leukemia, T-Cell Lymphoma of CNS, T Cell Prolymphocytic Leukemia, T Cell Childhood ALL
    View official trial listing →
  • Recruiting NCT NCT06486051

    A Study of Atlacabtagene Autoleucel CAR T-cells for Adults With Relapsed Large B-cell Lymphoma

    Not yet reported Malaghan Institute of Medical Research 60 participants Est. completion 2029-06-30 3 sites Stand-alone
    Other conditions: Large B-cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Primary Mediastinal Large B-cell Lymphoma (PMBCL), Transformed Non-Hodgkin Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06500819

    Autologous B7-H3 Chimeric Antigen Receptor T Cells in Relapsed/Refractory Solid Tumors

    Not yet reported Stanford University 41 participants Est. completion 2029-07 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Neuroblastoma, Sarcoma
    View official trial listing →
  • Recruiting NCT NCT06503237

    Safety and Efficacy of SWK002 in Patients With D2T-Rheumatoid Arthritis

    Not yet reported The First Affiliated Hospital of University of Science and Technology of China 18 participants Est. completion 2026-03 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Recruiting NCT NCT06515314

    HRYZ-T102 TCR-T Cell for AFP Positive Advanced HCC and Other Solid Tumors

    Not yet reported Shanghai Ruiliyuan Biotechnology Co., Ltd. 12 participants Est. completion 2027-08-10 1 site Stand-alone
    Other conditions: Hepatic Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT06517641

    Clinical Trial of Upfront Haploidentical or Unrelated Donor BMT to Restore Normal Hematopoiesis in Aplastic Anemia

    Not yet reported Medical College of Wisconsin 60 participants Est. completion 2029-02-01 25 sites
    Other conditions: Severe Aplastic Anemia
    View official trial listing →
  • Recruiting NCT NCT06532812

    TIL Gean Therapy Combined With Immunotherapy for Advanced or Metastatic Refractory Breast Cancer

    Not yet reported, Not yet reported Essen Biotech 85 participants Est. completion 2026-12-28 1 site Stand-alone
    Other conditions: Breast Cancer, Breast Carcinoma, Breast Cancer Metastatic, Breast Cancer Triple Negative
    View official trial listing →
  • Recruiting NCT NCT06546150

    RE002 T Cell Injection for the Treatment of KRAS G12D Mutated Solid Tumors

    Not yet reported Henan Cancer Hospital 30 participants Est. completion 2027-04-01 1 site Stand-alone
    Other conditions: KRAS G12D, T Cell Therapy
    View official trial listing →
  • Recruiting NCT NCT06550141

    Emapalumab Prevention of CAR-T Cell Associated Toxicities

    Not yet reported Marcela V. Maus, M.D.,Ph.D. 28 participants Est. completion 2027-08-01 2 sites Stand-alone
    Other conditions: Large B-cell Lymphoma, Relapsed Non-Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal Large B-cell Lymphoma, High-grade B-cell Lymphoma, Follicular Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06581562

    Open-label Single-Center Study to Evaluate the Safety and Efficacy of Combining Rituximab and AB-101 in B-cell Associated Autoimmune Diseases.

    Not yet reported IRIS Research and Development, LLC 30 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis, Pemphigus Vulgaris, Granulomatosis With Polyangiitis, Systemic Lupus Erythematosus
    View official trial listing →
  • Recruiting NCT NCT06652243

    Clinical Study of SN301A Injection in the Treatment of Hepatocellular Carcinoma

    Not yet reported Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 12 participants Est. completion 2027-10-31 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma (HCC)
    View official trial listing →
  • Recruiting NCT NCT06688799

    Anti-CD19 Chimeric Antigen Receptor T Cells for Refractory Autoimmune Diseases

    Not yet reported, Not yet reported Beijing GoBroad Hospital 18 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Autoimmune Diseases
    View official trial listing →
  • Recruiting NCT NCT06689917

    JY231(JY231) Injection for the Treatment of Relapsed or Refractory B Cell Lymphoma/ Leukemia

    Not yet reported Tongji Hospital 20 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: B-ALL, B-NHL
    View official trial listing →
  • Recruiting NCT NCT06720324

    CD7-specific CAR-T Cell in the Treatment of CD7-positive Relapsed/Refractory Hematologic Tumors

    Not yet reported, Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Hematologic Malignancy
    View official trial listing →
  • Recruiting NCT NCT06728189

    A Clinical Research About CD70-targeted CAR-NKT Cells Therapy in Subjects with Advanced Malignant Solid Tumors

    Not yet reported Peking University Cancer Hospital & Institute 13 participants Est. completion 2026-10-17 1 site Stand-alone
    Other conditions: Advanced Malignant Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT06815003

    Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning

    Not yet reported City of Hope Medical Center 35 participants Est. completion 2028-10-15 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Graft Versus Host Disease, Myelodysplastic Syndrome, Myeloproliferative Neoplasm
    View official trial listing →
  • Recruiting NCT NCT06826118

    Axicabtagene Ciloleucel Injection in Patients With Relapsed/Refractory Follicular Lymphoma

    Not yet reported The First Affiliated Hospital of Xiamen University 30 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Lymphoma, Follicular Lymphoma, Refractory Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06834282

    CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

    Not yet reported CERo Therapeutics Holdings, Inc. 18 participants Est. completion 2029-12-31 5 sites Stand-alone
    Other conditions: AML, Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT06847269

    CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia

    Not yet reported St. Jude Children's Research Hospital 25 participants Est. completion 2031-04 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT06865664

    FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory Rhabdomyosarcoma

    Not yet reported National Cancer Institute (NCI) 50 participants Est. completion 2029-04-01 1 site Stand-alone
    Obstructive sleep apnea
    View official trial listing →
  • Recruiting NCT NCT06904066

    Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies

    Not yet reported National Cancer Institute (NCI) 86 participants Est. completion 2029-04-30 1 site Stand-alone
    Other conditions: Malignancy, Hematologic, Neoplasms, Hematologic, Neoplasms, Hematopoietic, Blood Cancer, Hematological Neoplasms, Hematopoietic Malignancies, Dysmyelopoietic Syndromes, Hematopoetic Myelodysplasia, Myeloid Leukemia, Acute, Nonlymphoblastic Leukemia, Acute, Leukemia, Lymphocytic, Acute
    View official trial listing →
  • Recruiting NCT NCT06912152

    MT027 in Patients With Advanced Peritoneal Malignancies or Abdominal Metastatic Solid Tumors

    Not yet reported Zhejiang University 12 participants Est. completion 2028-12-31 1 site Stand-alone
    Other conditions: B7-H3-positive Advanced Malignant Solid Tumors Advanced Primary Peritoneal Tumors or Secondary Abdominal Metastatic Malignant Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT06925464

    CD7 CAR T-Cell Therapy for r/r T-cell Lymphomas

    Not yet reported, Not yet reported Beijing GoBroad Hospital 36 participants Est. completion 2027-04-01 4 sites Stand-alone
    Other conditions: T-Cell Non-Hodgkin Lymphoma, T-cell Lymphoma (PTCL and CTCL)
    View official trial listing →
  • Recruiting NCT NCT06930651

    A Phase I/II Study of CAR.70-Engineered IL15-Transduced Cord Blood-Derived NK Cells With TGF-beta Receptor 2 (TGFBR2) Knock Out in Conjunction With Lymphodepleting Chemotherapy for the Management of Relapsed/Refractory Myeloid Malignancies

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 42 participants Est. completion 2030-05-01 1 site Stand-alone
    Other conditions: Myeloid Malignancies
    View official trial listing →
  • Recruiting NCT NCT06945523

    Clinical Study on Chimeric Antigen Receptor T Lymphocyte (CAR-T) Targeting CEA for the Treatment of CEA - Positive Advanced Lung Cancer

    Not yet reported Chongqing Precision Biotech Co., Ltd 60 participants Est. completion 2028-04-30 1 site Stand-alone
    Other conditions: Advanced Lung Cancer
    View official trial listing →
  • Recruiting NCT NCT06946225

    ACTengine® IMA203 Combined With mRNA-4203

    Not yet reported Immatics US, Inc. 15 participants Est. completion 2029-08 4 sites Stand-alone
    Other conditions: Cutaneous Melanoma, Synovial Sarcoma
    View official trial listing →
  • Recruiting NCT NCT06947473

    Umbilical Cord Blood CD19-BCMA CART Cell Therapy for SLE-LN, SSc, andpSS PAH.

    Not yet reported, Not yet reported Beijing GoBroad Hospital 45 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Refractory Lupus Nephritis, Systemic Sclerosis, Primary Sjogren's Syndrome Combined With Pulmonary Hypertension
    View official trial listing →
  • Recruiting NCT NCT06996132

    Bispecific Antibody-Based Salvage Therapy Followed by CAR-T ± ASCT in R/R Aggressive B-Cell Lymphoma

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 25 participants Est. completion 2027-12-30 1 site Stand-alone
    Other conditions: Relapsed or Refractory Aggressive B-cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07004647

    MT027 Cell Injection in Patients With Advanced Primary or Secondary Peritoneal Tumors

    Not yet reported Ruijin Hospital 10 participants Est. completion 2028-11-30 1 site Stand-alone
    Other conditions: Peritoneal Tumor
    View official trial listing →
  • Recruiting NCT NCT07010523

    Anti-Mesothelin CAR-T Cell Injection in Patients With Mesothelin-positive Advanced Malignant Solid Tumors

    Not yet reported First Affiliated Hospital of Zhejiang University 24 participants Est. completion 2027-10-14 1 site Stand-alone
    Other conditions: Mesothelin-positive Advanced Malignant Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT07022197

    Safety and Efficacy of BAFF-R CART for Refractory Neuroimmune Diseases

    Not yet reported, Not yet reported Tianjin Medical University General Hospital 27 participants Est. completion 2027-12-30 1 site Stand-alone
    Other conditions: Chronic Inflammatory Demyelinating Polyradiculoneuropathy, NMO Spectrum Disorder, Myasthenia Gravis, Idiopathic Inflammatory Myopathies
    View official trial listing →
  • Recruiting NCT NCT07066995

    Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

    Not yet reported, Not yet reported Essen Biotech 60 participants Est. completion 2028-12-28 1 site Stand-alone
    Other conditions: Pancreatic Cancer, Pancreatic Carcinoma, Pancreatic Cancer Non-resectable, Pancreatic Cancer Stage IV
    View official trial listing →
  • Recruiting NCT NCT07093073

    Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma

    Not yet reported Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd 30 participants Est. completion 2029-01-31 1 site Stand-alone
    Other conditions: B Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07115745

    A Study of Healthy Donor CD19-targeted Allogeneic CAR T Cells in Participants With Severe, Refractory Autoimmune Diseases

    Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 125 participants Est. completion 2030-08-16 28 sites Stand-alone
    Other conditions: Refractory Autoimmune Diseases
    View official trial listing →
  • Recruiting NCT NCT07203404

    A Study of Anti-CD19/BCMA Universal CAR-T Cell Therapy RD06-05 in Patients With Autoimmune Diseases.

    Not yet reported Nanjing Bioheng Biotech Co., Ltd. 96 participants Est. completion 2028-07-23 1 site Stand-alone
    Other conditions: SLE, LN, ANCA Associated Vasculitis, ANCA-Associated Glomerulonephritis, Anti-GBM Disease, MN, SSc, IIM, IgA Nephropathy
    View official trial listing →
  • Recruiting NCT NCT07225439

    Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

    Not yet reported Paolo Caimi, MD 15 participants Est. completion 2027-12 2 sites Stand-alone
    Other conditions: Non Hodgkin Lymphoma, B-cell Non Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, High-grade B-cell Lymphoma, Primary Mediastinal Large B Cell Lymphoma, Follicular Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07228624

    Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes

    Not yet reported Fred Hutchinson Cancer Center 50 participants Est. completion 2030-09-01 1 site Stand-alone
    Other conditions: Myelodysplastic/Myeloproliferative Neoplasm, Primary Myelofibrosis, Secondary Myelofibrosis
    View official trial listing →
  • Recruiting NCT NCT07242417

    TC-G203 for Patients With GPC3-Positive Advanced Solid Tumors

    Not yet reported Beijing GoBroad Hospital 30 participants Est. completion 2027-11-01 2 sites Stand-alone
    Other conditions: Solid Cancer, GPC3 Positive Hepatocellular Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07246096

    Exploratory Clinical Study on the Safety and Efficacy of Anti- CD19/BCMA U CAR-T Cell Injection for the Treatment of Relapsed/Refractory Autoimmune Diseases

    Not yet reported Changhai Hospital 60 participants Est. completion 2028-07-20 1 site Stand-alone
    Other conditions: Autoimmune Diseases, Systemic Lupus Erythematosus, Systemic Sclerosis, Primary Sjögren Syndrome, Rheumatoid Arthritis, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
    View official trial listing →
  • Recruiting NCT NCT07275736

    A Study of CNCT19 in the Treatment of Relapsed or Refractory Neurological Autoimmune Diseases

    Not yet reported Juventas Cell Therapy Ltd. 18 participants Est. completion 2029-06-01 1 site Stand-alone
    Other conditions: Neurological Autoimmune Diseases
    View official trial listing →
  • Recruiting NCT NCT07368270

    Safety and Efficacy Study of Anti-PD1 Armored CD19 CAR-T Cells in Adult Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma

    Not yet reported Jiangsu Topcel-KH Pharmaceutical Co., Ltd. 30 participants Est. completion 2029-01 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07493538

    MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

    Not yet reported Masonic Cancer Center, University of Minnesota 132 participants Est. completion 2035-03 1 site Stand-alone
    Other conditions: AML, MDS, Acute Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Recruiting NCT NCT07502287

    Dual-Target GD2/B7-H3 CAR-NK Cells for Pediatric Relapsed or Refractory Neuroblastoma

    Not yet reported, Not yet reported Beijing Biotech 36 participants Est. completion 2028-06-17 1 site Stand-alone
    Other conditions: Relapsed Neuroblastoma, Refractory Neuroblastoma, High-Risk Neuroblastoma, Ganglioneuroblastoma
    View official trial listing →
  • Recruiting NCT NCT07510802

    Dual-Target CAR-NK Cells for Advanced Breast Cancer HER2+ TNBC

    Not yet reported, Not yet reported Beijing Biotech 60 participants Est. completion 2028-04-17 1 site Stand-alone
    Other conditions: Breast Cancer (Advanced/Metastatic), HER2-positive Breast Cancer, Triple-negative Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT07523529

    Biomarker-Guided Dual-Target CAR-T Cells for Advanced Solid Tumors

    Not yet reported, Not yet reported Beijing Biotech 72 participants Est. completion 2028-03-17 1 site Stand-alone
    Other conditions: Advanced Unresectable, Metastatic
    View official trial listing →
  • Recruiting NCT NCT07523542

    SELECT-SLE: Biomarker-Guided CAR-T Target Selection for Refractory Lupus

    Not yet reported, Not yet reported Beijing Biotech 24 participants Est. completion 2028-10-17 1 site Stand-alone
    Other conditions: REFRACTORY SYSTEMIC LUPUS ERYTHEMATOSUS, Lupus Nephritis
    View official trial listing →
  • Recruiting NCT NCT07523555

    Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

    Not yet reported, Not yet reported Beijing Biotech 96 participants Est. completion 2028-02-17 1 site Stand-alone
    Other conditions: Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, Relapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLL, Relapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia, Relapsed/Refractory Acute Myeloid Leukemia, High-risk Myelodysplastic Neoplasm, BPDCN; Relapsed/Refractory T-cell Acute Lymphoblastic Leukemia, T-lymphoblastic Lymphoma, Peripheral T-cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07564232

    Phase 1 Study Of LNK001 In Advanced Or Metastatic Clear Cell Renal Cell Carcinoma

    Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2033-06-06 1 site Stand-alone
    Other conditions: Clear Cell Renal Cell Carcinoma
    View official trial listing →
  • Recruiting NCT NCT07582172

    Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome

    Not yet reported City of Hope Medical Center 35 participants Est. completion 2029-04-05 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia With Complex Karyotype, Myelodysplastic Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Secondary Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome, Refractory Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07584889

    Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies

    Not yet reported, Not yet reported Shenzhen University General Hospital 10 participants Est. completion 2029-04-19 1 site Stand-alone
    Other conditions: B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
    View official trial listing →
  • Recruiting NCT NCT07587125

    Safety and Efficacy of S103 Cells in Progressive/Refractory Multiple Sclerosis

    Not yet reported Xijing Hospital 9 participants Est. completion 2029-11 1 site Stand-alone
    Other conditions: Multiple Sclerosis (MS) Primary Progressive, Multiple Sclerosis, Multiple Sclerosis (MS) Secondary Progressive, Refractory Multiple Sclerosis
    View official trial listing →
  • Recruiting NCT NCT07589517

    Dual-Targeting CAR-NK Cells in Biomarker-Selected Advanced Colorectal Cancer

    Not yet reported, Not yet reported Beijing Biotech 48 participants Est. completion 2028-03-17 1 site Stand-alone
    Other conditions: Colorectal Cancer, Metastatic Colorectal Adenocarcinoma, Unresectable Colorectal Cancer
    View official trial listing →
  • Recruiting NCT NCT07589530

    Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors

    Not yet reported, Not yet reported Beijing Biotech 60 participants Est. completion 2028-03-17 1 site Stand-alone
    Other conditions: Advanced Solid Tumors, Metastatic Solid Tumors, TROP2-Expressing Solid Tumors
    View official trial listing →
  • Recruiting NCT NCT07641049

    Dual-target PSMA/PSCA CAR-NK Cells in Advanced Prostate Cancer

    Not yet reported Beijing Biotech 36 participants Est. completion 2028-06-17 1 site Stand-alone
    Other conditions: Metastatic Castration-resistant Prostate Cancer, Advanced Prostate Adenocarcinoma, PSCA-positive Prostate Cancer, PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer
    View official trial listing →
  • Recruiting NCT NCT07673367

    Nemtabrutinib With CAR T Therapy in Relapsed/Refractory Mantle Cell Lymphoma

    Not yet reported Vanderbilt-Ingram Cancer Center 25 participants Est. completion 2032-07-31 1 site Stand-alone
    Other conditions: Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00001676

    Cyclophosphamide and Fludarabine to Treat Lupus Nephritis

    Not yet reported National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS) 15 participants Est. completion 2002-11 1 site
    Other conditions: Glomerulonephritis, Lupus Nephritis, Systemic Lupus Erythematosus
    View official trial listing →
  • Completed NCT NCT00002798

    Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

    Not yet reported National Cancer Institute (NCI) 880 participants 1 site Stand-alone
    Other conditions: Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Childhood Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Secondary Myelodysplastic Syndromes, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies
    View official trial listing →
  • Completed NCT NCT00003145

    Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Older Patients With Chronic Myeloid Leukemia

    Not yet reported Fred Hutchinson Cancer Center 18 participants 8 sites Stand-alone
    Other conditions: Accelerated Phase of Disease, Childhood Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase of Disease, Recurrent Disease
    View official trial listing →
  • Completed NCT NCT00003764

    Fludarabine With or Without Cyclophosphamide in Treating Patients With Chronic Lymphocytic Leukemia

    Not yet reported Eastern Cooperative Oncology Group 280 participants 218 sites
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00004135

    Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Metastatic Kidney Cancer

    Not yet reported University of Chicago 19 participants Est. completion 2007-08 1 site Stand-alone
    Other conditions: Kidney Cancer, Melanoma (Skin)
    View official trial listing →
  • Completed NCT NCT00004218

    Chemotherapy in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

    Not yet reported Leukemia Research Fund Est. completion 2007-07 86 sites
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00004255

    Treatment of Bone Marrow to Prevent Graft-Versus-Host Disease in Patients With Acute or Chronic Leukemia Undergoing Bone Marrow Transplantation

    Not yet reported, Not yet reported Chimeric Therapies Est. completion 2003-05 15 sites
    Other conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00005785

    Stem Cell (Modified Bone Marrow) Transplantation in HIV-Infected Patients With Blood Cancer

    Not yet reported National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 30 participants Est. completion 2001-11 1 site
    Other conditions: Hematologic Neoplasm, HIV Infection
    View official trial listing →
  • Completed NCT NCT00005802

    Chemotherapy Followed by Donor White Blood Cells Plus Interleukin-2 in Treating Patients With Acute Myeloid or Lymphocytic Leukemia

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center Est. completion 2005-03 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00005898

    Phase I/II Study of Total Body Irradiation, Cyclophosphamide, and Fludarabine Followed by Alternate Donor Hematopoietic Cell Transplantation in Patients With Fanconi's Anemia

    Not yet reported, Not yet reported University of Minnesota 30 participants 1 site
    Other conditions: Fanconi's Anemia
    View official trial listing →
  • Completed NCT NCT00006251

    Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 21 participants 2 sites Stand-alone
    Obstructive sleep apnea Other conditions: Acute Undifferentiated Leukemia, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Grade III Lymphomatoid Granulomatosis, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Myeloid/NK-cell Acute Leukemia, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Systemic Amyloidosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Renal Cell Cancer, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00008151

    Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome

    Not yet reported Fred Hutchinson Cancer Center Est. completion 2002-07 1 site
    Other conditions: Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00008177

    Radiolabeled Monoclonal Antibody Therapy, Fludarabine Phosphate, and Low-Dose Total-Body Irradiation Followed by Donor Stem Cell Transplant and Immunosuppression Therapy in Treating Older Patients With Advanced Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes

    Not yet reported Fred Hutchinson Cancer Center 79 participants Est. completion 2010-12-15 1 site Stand-alone
    Other conditions: Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Chronic Myelomonocytic Leukemia, de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Anemia With Ringed Sideroblasts, Refractory Cytopenia With Multilineage Dysplasia, Secondary Myelodysplastic Syndromes, Untreated Adult Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00014235

    Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies

    Not yet reported Fred Hutchinson Cancer Center 160 participants 11 sites Stand-alone
    Obstructive sleep apnea Other conditions: Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Plasmacytoid Dendritic Cell Neoplasm, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Systemic Amyloidosis, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Multiple Myeloma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00024440

    Fludarabine and Cyclophosphamide With or Without Oblimersen in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia

    Not yet reported Genta Incorporated Est. completion 2007-02 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Withdrawn NCT NCT00025519

    Peripheral Stem Cell Transplantation in Treating Patients With Metastatic or Recurrent Kidney Cancer

    Not yet reported Fox Chase Cancer Center Est. completion 2006-10
    Other conditions: Kidney Cancer
    View official trial listing →
  • Completed NCT NCT00027820

    Total-Body Irradiation and Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 106 participants Est. completion 2004-09-05 10 sites Stand-alone
    Other conditions: Adult Acute Myeloid Leukemia in Remission, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndrome, Childhood Renal Cell Carcinoma, Chronic Myelomonocytic Leukemia, Clear Cell Renal Cell Carcinoma, de Novo Myelodysplastic Syndrome, Metastatic Renal Cell Cancer, Previously Treated Myelodysplastic Syndrome, Progression of Multiple Myeloma or Plasma Cell Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Non-Hodgkin Lymphoma, Refractory Anemia, Refractory Anemia With Ringed Sideroblasts, Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Renal Medullary Carcinoma, Type 1 Papillary Renal Cell Carcinoma, Type 2 Papillary Renal Cell Carcinoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT00031005

    Stem Cell Transplantation to Treat Leukocyte Adhesion Deficiency

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 10 participants Est. completion 2003-02 1 site
    Other conditions: Leukocyte-Adhesion Deficiency Syndrome
    View official trial listing →
  • Completed NCT NCT00038844

    Safety and Efficacy of Campath in Nonmyeloablative Transplantation

    Not yet reported M.D. Anderson Cancer Center 65 participants Est. completion 2010-09 1 site Stand-alone
    Other conditions: Lymphoma, Leukemia
    View official trial listing →
  • Completed NCT NCT00045435

    Reduced Intensity Donor Peripheral Blood Stem Cell Transplant in Treating Patients With De Novo or Secondary Acute Myeloid Leukemia in Remission

    Not yet reported Fred Hutchinson Cancer Center 17 participants Est. completion 2009-01 2 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00048737

    Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 70 participants Est. completion 2011-12 1 site Stand-alone
    Other conditions: Lymphoma, Leukemia
    View official trial listing →
  • Completed NCT NCT00049075

    Fludarabine in Treating Patients With Chronic Lymphocytic Leukemia

    Not yet reported NCIC Clinical Trials Group 128 participants Est. completion 2009-12-21 34 sites
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00049504

    Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer

    Not yet reported Fred Hutchinson Cancer Center 53 participants Est. completion 2014-02 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Hematopoietic/Lymphoid Cancer, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Childhood Hodgkin Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00056966

    Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation of Patients With Hematological Diseases

    Not yet reported, Not yet reported Baylor College of Medicine 24 participants Est. completion 2006-12 2 sites Stand-alone
    Other conditions: Hematologic Malignancy
    View official trial listing →
  • Completed NCT NCT00062036

    Cyclophosphamide and Fludarabine Followed By Interleukin-2 Gene-Modified Tumor Infiltrating Lymphocytes in Treating Patients With Metastatic Melanoma

    Not yet reported, Not yet reported National Institutes of Health Clinical Center (CC) 33 participants Est. completion 2008-09 2 sites
    Other conditions: Melanoma (Skin)
    View official trial listing →
  • Completed NCT NCT00067002

    Randomized Double Cord Blood Transplant Study

    Not yet reported M.D. Anderson Cancer Center 110 participants Est. completion 2016-07 1 site Stand-alone
    Other conditions: Leukemia, Lymphocytic, Acute, Leukemia, Myelocytic, Acute, Leukemia, Myeloid, Chronic, Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT00068315

    Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

    Not yet reported National Cancer Institute (NCI) 18 participants 7 sites Stand-alone
    Obstructive sleep apnea Other conditions: Hematopoietic/Lymphoid Cancer, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00068523

    Ultraviolet-B Light Therapy and Allogeneic Stem Cell Transplantation in Treating Patients With Hematologic Malignancies

    Not yet reported Case Comprehensive Cancer Center 10 participants 1 site
    Other conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
    View official trial listing →
  • Terminated NCT NCT00069992

    Total-Body Irradiation, Fludarabine, and Alemtuzumab Followed By Stem Cell Transplant in Treating Patients With Myeloproliferative Disorder, MS, AML, or CML

    Not yet reported Baylor College of Medicine 7 participants Est. completion 2007-04 2 sites Stand-alone
    Other conditions: Chronic Myeloproliferative Disorders, Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00076752

    Lymphocyte Depletion and Stem Cell Transplantation to Treat Severe Systemic Lupus Erythematosus

    Not yet reported National Cancer Institute (NCI) 9 participants Est. completion 2013-10-15 1 site Stand-alone
    Other conditions: Lupus Erythematosus, Systemic
    View official trial listing →
  • Completed NCT NCT00078065

    Xcellerated T CellsTM in Patients With Multiple Myeloma

    Not yet reported Xcyte Therapies 30 participants Est. completion 2004-06 9 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00078234

    Genasense® (Oblimersen Sodium), Fludarabine, and Rituximab in Subjects With Chronic Lymphocytic Leukemia

    Not yet reported, Not yet reported Genta Incorporated 25 participants Est. completion 2010-09 3 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00085423

    Cyclophosphamide, Fludarabine, and High-Dose Interleukin-2 in Treating Patients With Metastatic Melanoma

    Not yet reported Dartmouth-Hitchcock Medical Center 20 participants Est. completion 2010-02 1 site Stand-alone
    Other conditions: Melanoma (Skin)
    View official trial listing →
  • Completed NCT NCT00089011

    Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer

    Not yet reported Fred Hutchinson Cancer Center 150 participants Est. completion 2018-07 5 sites Stand-alone
    Obstructive sleep apnea Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Essential Thrombocythemia, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Polycythemia Vera, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Primary Myelofibrosis, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Childhood Anaplastic Large Cell Lymphoma, Stage I Childhood Large Cell Lymphoma, Stage I Childhood Lymphoblastic Lymphoma, Stage I Childhood Small Noncleaved Cell Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Small Lymphocytic Lymphoma, Stage IA Mycosis Fungoides/Sezary Syndrome, Stage IB Mycosis Fungoides/Sezary Syndrome, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Childhood Anaplastic Large Cell Lymphoma, Stage II Childhood Large Cell Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage II Childhood Small Noncleaved Cell Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Multiple Myeloma, Stage IIA Mycosis Fungoides/Sezary Syndrome, Stage IIB Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Childhood Anaplastic Large Cell Lymphoma, Stage III Childhood Large Cell Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage III Childhood Small Noncleaved Cell Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IIIA Mycosis Fungoides/Sezary Syndrome, Stage IIIB Mycosis Fungoides/Sezary Syndrome, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Childhood Anaplastic Large Cell Lymphoma, Stage IV Childhood Large Cell Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Childhood Small Noncleaved Cell Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Stage IVA Mycosis Fungoides/Sezary Syndrome, Stage IVB Mycosis Fungoides/Sezary Syndrome, Testicular Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Untreated Childhood Acute Lymphoblastic Leukemia, Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00096018

    Fludarabine and Thalidomide in Treating Patients With Newly Diagnosed Chronic Lymphocytic Leukemia

    Not yet reported, Not yet reported Roswell Park Cancer Institute 43 participants Est. completion 2012-05 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00096382

    Cyclophosphamide, Fludarabine, and Total-Body Irradiation Followed By Cellular Adoptive Immunotherapy, Autologous Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Metastatic Melanoma

    Not yet reported National Institutes of Health Clinical Center (CC) 34 participants Est. completion 2009-01 2 sites
    Other conditions: Melanoma (Skin)
    View official trial listing →
  • Completed NCT NCT00103558

    Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)

    Not yet reported, Not yet reported Biogen 31 participants Est. completion 2010-03 5 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00104858

    Fludarabine Phosphate, Radiation Therapy, and Rituximab in Treating Patients Who Are Undergoing Donor Stem Cell Transplant Followed by Rituximab for High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

    Not yet reported Fred Hutchinson Cancer Center 66 participants Est. completion 2018-03-30 5 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Stage III Chronic Lymphocytic Leukemia, Stage III Small Lymphocytic Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Small Lymphocytic Lymphoma, T-Cell Large Granular Lymphocyte Leukemia
    View official trial listing →
  • Terminated NCT NCT00113828

    Non-Myeloablative HLA-Matched Ex-Vivo T-cell Depleted Stem Cell Transplantation for Hematologic Malignancies

    Not yet reported Massachusetts General Hospital 5 participants Est. completion 2007-03 1 site Stand-alone
    Other conditions: Lymphoma, Leukemia, Multiple Myeloma, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00117156

    Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma

    Not yet reported Dana-Farber Cancer Institute 26 participants Est. completion 2012-01 4 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin, MALT Lymphoma
    View official trial listing →
  • Completed NCT NCT00119392

    Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

    Not yet reported Fred Hutchinson Cancer Center 42 participants Est. completion 2016-04-23 1 site Stand-alone
    Other conditions: B-cell Chronic Lymphocytic Leukemia, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT00138229

    Cyclophosphamide and Fludarabine Followed By an Autologous Lymphocyte Infusion and Interleukin-2 in Treating Patients With Refractory or Recurrent Metastatic Melanoma

    Not yet reported National Institutes of Health Clinical Center (CC) 6 participants Est. completion 2007-04 2 sites
    Other conditions: Melanoma (Skin)
    View official trial listing →
  • Completed NCT NCT00140569

    Randomized Study for Patients With Follicular Lymphoma Needing Treatment

    Not yet reported Lymphoma Study Association 400 participants Est. completion 2004-01 8 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Terminated NCT NCT00167206

    Stem Cell Transplantation for Fanconi Anemia

    Not yet reported, Not yet reported Masonic Cancer Center, University of Minnesota 16 participants Est. completion 2008-12 1 site Stand-alone
    Other conditions: Fanconi Anemia
    View official trial listing →
  • Completed NCT NCT00169208

    Fludarabine, Mitoxantrone and Rituximab in Relapsed or Primary Failing Advanced Follicular Non-Hodgkin's Lymphoma

    Not yet reported Lymphoma Study Association 50 participants Est. completion 2006-12 16 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00176852

    Stem Cell Transplant for Hemoglobinopathy

    Not yet reported, Not yet reported Masonic Cancer Center, University of Minnesota 22 participants Est. completion 2020-01 1 site Stand-alone
    Other conditions: Sickle Cell Disease, Thalassemia, Severe Congenital Neutropenia, Diamond-Blackfan Anemia, Shwachman-Diamond Syndrome
    View official trial listing →
  • Completed NCT NCT00186797

    Purified CD34+ Hematopoietic Stem Cell Transplantation From Alternate Donors for Patients With Severe Aplastic Anemia

    Not yet reported St. Jude Children's Research Hospital 28 participants Est. completion 2007-05 1 site
    Other conditions: Aplastic Anemia
    View official trial listing →
  • Completed NCT NCT00187096

    Natural Killer (NK) Cell Transplantation for AML

    Not yet reported St. Jude Children's Research Hospital 49 participants Est. completion 2013-03 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00198991

    German Multicenter Trial for Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Adults (07/2003)

    Not yet reported Goethe University 1883 participants Est. completion 2013-06-30 1 site Stand-alone
    Other conditions: Adult Acute Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT00208975

    Phase II Study of Fludarabine and Mitoxantrone, Followed by GM-CSF(Granulocyte-macrophage Colony-stimulating Factor) and Rituximab

    Not yet reported Emory University 15 participants Est. completion 2011-09 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00220311

    A Study to Confirm the Efficacy and Safety of Fludarabine Phosphate Administered in Untreated Chronic Lymphocytic Leukemia Patients With Anemia and/or Thrombocytopenia

    Not yet reported Genzyme, a Sanofi Company 10 participants Est. completion 2005-09 Stand-alone
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Completed NCT NCT00245037

    Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer

    Not yet reported, Not yet reported OHSU Knight Cancer Institute 147 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms, Precancerous Condition
    View official trial listing →
  • Completed NCT NCT00258427

    Hematopoietic Stem Cell Transplantation in High Risk Patients With Fanconi Anemia

    Not yet reported Masonic Cancer Center, University of Minnesota 14 participants Est. completion 2020-10-10 1 site Stand-alone
    Other conditions: Fanconi Anemia
    View official trial listing →
  • Completed NCT NCT00275678

    Comparison of Peripheral Blood Stem Cell Transplantation With Bone Marrow Transplantation for the Treatment of Serious Hematological Malignancies

    Not yet reported Mayo Clinic 15 participants 1 site
    Other conditions: Blood Stem Cell Transplant
    View official trial listing →
  • Completed NCT NCT00276809

    Combination Chemotherapy, Total-Body Irradiation, and Alemtuzumab in Treating Patients Undergoing an Autologous Stem Cell Transplant for Stage I, Stage II, Stage III, or Stage IV Chronic Lymphocytic Leukemia

    Not yet reported German CLL Study Group 30 participants Est. completion 2004-09 12 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00276848

    Fludarabine With or Without Cyclophosphamide in Treating Patients With Advanced Chronic Lymphocytic Leukemia

    Not yet reported German CLL Study Group 375 participants Est. completion 2007-07 135 sites
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT00278512

    Hematopoietic Stem Cell Support in Vasculitis

    Not yet reported Northwestern University 7 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Vasculitis
    View official trial listing →
  • Terminated NCT NCT00282412

    Rheumatoid Arthritis:Tolerance Induction by Mixed Chimerism

    Not yet reported Northwestern University 4 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Completed NCT NCT00289549

    Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)

    Not yet reported BioCryst Pharmaceuticals 8 participants Est. completion 2009-01 1 site
    Other conditions: Leukemia, Lymphocytic, Chronic
    View official trial listing →
  • Completed NCT NCT00295971

    Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease

    Not yet reported University of California, San Francisco 21 participants Est. completion 2011-12 2 sites Stand-alone
    Other conditions: Congenital Amegakaryocytic Thrombocytopenia, Leukemia, Myelodysplastic Syndromes, Severe Congenital Neutropenia
    View official trial listing →
  • Status unknown NCT NCT00295997

    Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer, Metastatic Kidney Cancer, or Aplastic Anemia

    Not yet reported University of California, San Francisco 35 participants 2 sites
    Other conditions: Chronic Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
    View official trial listing →
  • Completed NCT NCT00305708

    Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission

    Not yet reported, Not yet reported University of California, San Francisco 40 participants Est. completion 2004-07 1 site
    Other conditions: Congenital Amegakaryocytic Thrombocytopenia, Diamond-blackfan Anemia, Fanconi Anemia, Leukemia, Severe Congenital Neutropenia, Thrombocytopenia
    View official trial listing →
  • Completed NCT NCT00322101

    Low-Dose or High-Dose Conditioning Followed by Peripheral Blood Stem Cell Transplant in Treating Patients With Myelodysplastic Syndrome or Acute Myelogenous Leukemia

    Not yet reported Fred Hutchinson Cancer Center 25 participants Est. completion 2014-10 8 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Acute Myeloid Leukemia/Transient Myeloproliferative Disorder, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Childhood Acute Myeloid Leukemia in Remission, Childhood Myelodysplastic Syndromes, de Novo Myelodysplastic Syndromes, Myelodysplastic Syndrome With Isolated Del(5q), Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes
    View official trial listing →
  • Status unknown NCT NCT00328237

    Treatment of Hematologic Malignancies With Single-Unit or Double-Unit Cord Blood Transplantation

    Not yet reported Colorado Blood Cancer Institute 20 participants 1 site
    Other conditions: Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia, Non-Hodgkin Lymphoma, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00337246

    Combination Chemotherapy With or Without Rituximab in Treating Patients With Previously Treated Chronic Lymphocytic Leukemia

    Not yet reported Cancer Research UK 56 participants Est. completion 2011-03 16 sites
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00343798

    A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies

    Not yet reported Fred Hutchinson Cancer Center 23 participants 4 sites Stand-alone
    Obstructive sleep apnea Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, de Novo Myelodysplastic Syndromes, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Prolymphocytic Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Anemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Childhood Lymphoblastic Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage II Childhood Lymphoblastic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Childhood Lymphoblastic Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Childhood Lymphoblastic Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT00354822

    Fludarabine,Cyclophosphamide and Rituximab Followed by Zevalin for Non-Follicular Indolent Lymphomas.

    Not yet reported A.O. Ospedale Papa Giovanni XXIII 25 participants Est. completion 2009-08 6 sites
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Terminated NCT NCT00358657

    Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation Followed by Donor Bone Marrow Transplant and Cyclophosphamide, Mycophenolate Mofetil, Tacrolimus, and Sirolimus in Treating Patients With Primary Immunodeficiency Disorders or Noncancerous Inherited Disorders

    Not yet reported Fred Hutchinson Cancer Center 14 participants Est. completion 2019-05-25 3 sites Stand-alone
    Other conditions: Immunodeficiency Syndrome, Severe Aplastic Anemia, Genetic Disorder
    View official trial listing →
  • Completed NCT NCT00365287

    Combination Chemotherapy and Total-Body Irradiation Before Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematologic Cancer, Metastatic Breast Cancer, or Kidney Cancer

    Not yet reported, Not yet reported Masonic Cancer Center, University of Minnesota 148 participants Est. completion 2005-12
    Other conditions: Breast Cancer, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00372619

    Clofarabine and Cytarabine in Treating Young Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia

    Not yet reported, Not yet reported Children's Oncology Group 74 participants Est. completion 2012-08 79 sites
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00376480

    Laboratory-Treated Lymphocyte Infusion After Haploidentical Donor Stem Cell Transplant

    Not yet reported Dana-Farber Cancer Institute 19 participants Est. completion 2018-05-16 6 sites Stand-alone
    Other conditions: Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Terminated NCT NCT00376519

    Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases

    Not yet reported Masonic Cancer Center, University of Minnesota 3 participants Est. completion 2008-03 1 site Stand-alone
    Other conditions: Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Secondary Myelofibrosis
    View official trial listing →
  • Completed NCT NCT00393029

    Phase II Study of Metastatic Cancer That Overexpresses P53 Using Lymphodepleting Conditioning Followed by Infusion of Anti-P53 TCR-Gene Engineered Lymphocytes

    Not yet reported National Cancer Institute (NCI) 12 participants Est. completion 2008-11 1 site Stand-alone
    Other conditions: Anti-p53 TCR-Gene
    View official trial listing →
  • Completed NCT NCT00393107

    Safety and Efficacy of Fludarabine and Cyclophosphamide + Rituximab

    Not yet reported Gruppo Italiano Studio Linfomi 54 participants Est. completion 2006-08 9 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00412360

    Single vs Double Umbilical Cord Blood Transplants in Children With High Risk Leukemia and Myelodysplasia (BMT CTN 0501)

    Not yet reported Medical College of Wisconsin 224 participants Est. completion 2014-10 38 sites Stand-alone
    Other conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndrome, Natural Killer Cell Lymphoblastic Leukemia/Lymphoma
    View official trial listing →
  • Terminated NCT NCT00416910

    Combination Chemotherapy With or Without G-CSF in Treating Patients With Relapsed Chronic Lymphocytic Leukemia

    Not yet reported German CLL Study Group 83 participants Est. completion 2007-09 Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00427557

    Cellular Therapy With Cord Blood Cells

    Not yet reported M.D. Anderson Cancer Center 31 participants Est. completion 2010-11 1 site Stand-alone
    Other conditions: Multiple Myeloma, Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00448201

    Reduced-Intensity Busulfan and Fludarabine With or Without Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease

    Not yet reported UNC Lineberger Comprehensive Cancer Center 71 participants Est. completion 2012-05-23 1 site
    Other conditions: Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
    View official trial listing →
  • Terminated NCT NCT00450983

    Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases

    Not yet reported Fred Hutchinson Cancer Center 1 participants Est. completion 2010-07 2 sites
    Other conditions: Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00455312

    Stem Cell Transplant (SCT) for Dyskeratosis Congenita or SAA

    Not yet reported, Not yet reported Masonic Cancer Center, University of Minnesota 36 participants Est. completion 2016-06 1 site Stand-alone
    Other conditions: Dyskeratosis Congenita, Aplastic Anemia
    View official trial listing →
  • Terminated NCT NCT00480987

    Oxaliplatin, Fludarabine, and Cytarabine in Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndromes (MDS)

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 27 participants Est. completion 2010-08 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes, Acute Myeloid Leukemia, Leukemia
    View official trial listing →
  • Completed NCT NCT00491634

    Treosulfan-based Conditioning for Transplantation in AML/MDS

    Not yet reported Dr. Avichai Shimoni MD 24 participants Est. completion 2014-06 1 site
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00520130

    Chemotherapy and Unrelated Donor Stem Cell Transplantation for Patients With Cancers of the Blood and Immune System

    Not yet reported, Not yet reported National Cancer Institute (NCI) 92 participants Est. completion 2018-12-31 1 site Stand-alone
    Other conditions: Myelodysplastic Syndrome, Hodgkin's Lymphoma, Non-Hodgkin's Disease, Acute Leukemia, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00536341

    Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

    Not yet reported, Not yet reported SCRI Development Innovations, LLC 64 participants Est. completion 2016-11 6 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT00543114

    Dose Escalation Study of Revlimid With Fludarabine-Rituximab for CLL/SLL

    Not yet reported Dana-Farber Cancer Institute 9 participants Est. completion 2012-12 2 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00582933

    Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated Donor

    Not yet reported Memorial Sloan Kettering Cancer Center 96 participants Est. completion 2009-04 1 site Stand-alone
    Other conditions: Leukemia, Myelodysplastic Syndrome, Non-Hodgkin's Lymphoma, Allogeneic Marrow Transplant
    View official trial listing →
  • Terminated NCT NCT00590460

    Antibody Conditioning Regimen For Allogeneic Donor Stem Cell Transplantation Of Patients With Fanconi Anemia

    Not yet reported, Not yet reported Baylor College of Medicine 5 participants Est. completion 2009-09 2 sites Stand-alone
    Other conditions: Fanconi Anemia, Severe Aplastic Anemia
    View official trial listing →
  • Completed NCT NCT00595127

    Hematopoietic Stem Cell Transplantation for Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using Total Body Irradiation, Cyclophosphamide and Fludarabine

    Not yet reported Memorial Sloan Kettering Cancer Center 21 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Fanconi Anemia
    View official trial listing →
  • Completed NCT NCT00602693

    T-Regulatory Cell Infusion Post Umbilical Cord Blood Transplant in Patients With Advanced Hematologic Cancer

    Not yet reported Masonic Cancer Center, University of Minnesota 41 participants Est. completion 2015-04-16 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma, Multiple Myeloma, Plasma Cell Neoplasm, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00603954

    Allogeneic HCT With HLA-matched Donors : a Phase II Randomized Study Comparing 2 Nonmyeloablative Conditionings

    Not yet reported University of Liege 107 participants Est. completion 2016-07 11 sites
    Other conditions: Hematological Malignancies
    View official trial listing →
  • Completed NCT NCT00645606

    Rituximab Maintenance Versus Observation After First-line Immunochemotherapy by FCR in Older Patients With Chronic Lymphocytic Leukemia

    Not yet reported University Hospital, Tours 542 participants Est. completion 2017-07 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00719888

    Umbilical Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With Hematologic Disease

    Not yet reported Fred Hutchinson Cancer Center 135 participants Est. completion 2024-12-19 3 sites Stand-alone
    Other conditions: Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Burkitt Lymphoma, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Follicular Lymphoma, Lymphoblastic Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Prolymphocytic Leukemia, Refractory Anemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT00732316

    Donor Stem Cell Transplant After Busulfan, Fludarabine, and Antithymocyte Globulin in Treating Patients With Hematologic Cancer or Myelodysplastic Syndrome

    Not yet reported Asan Medical Center 54 participants Est. completion 2011-05 1 site
    Other conditions: Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00741455

    Chemotherapy Followed by Allogeneic Stem Cell Transplantation for Hematologic Malignancies

    Not yet reported Dartmouth-Hitchcock Medical Center 18 participants Est. completion 2020-05-01 1 site Stand-alone
    Other conditions: Hematologic Malignancies
    View official trial listing →
  • Completed NCT NCT00744692

    Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders

    Not yet reported Duke University 22 participants Est. completion 2014-04 1 site
    Other conditions: Non Malignant Disorders, Immunodeficiencies, Congenital Marrow Failures, Hemoglobinopathies, Inborn Errors of Metabolism, Sickle Cell, Thalassemia, Lysosomal Storage Disease
    View official trial listing →
  • Completed NCT NCT00772486

    A Phase Ib Study of ISF35 in Combination With Chemotherapy (FCR) in Subjects With Relapsed, Refractory, and/or 17p- CLL

    Not yet reported Memgen, LLC 13 participants Est. completion 2013-04 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00774280

    Busulfan Plus Cyclophosphamide vs Fludarabine as a Conditioning Regimen

    Not yet reported Cooperative Study Group A for Hematology 130 participants Est. completion 2010-12 1 site
    Other conditions: Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00793351

    Reduced Intensity Stem Cell Transplantation in Children With Relapsed Neuroblastoma After Autologous Transplantation

    Not yet reported Samsung Medical Center 25 participants Est. completion 2015-11 1 site
    Other conditions: Neuroblastoma
    View official trial listing →
  • Completed NCT NCT00809276

    Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY

    Not yet reported, Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 92 participants Est. completion 2011-12 3 sites
    Other conditions: Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00812669

    CLL-Irl Study. CTRIAL-IE (ICORG) 07-01, V7

    Not yet reported Cancer Trials Ireland 52 participants Est. completion 2019-11-21 7 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00822770

    Plerixafor and Granulocyte Colony-stimulating Factor (G-CSF) With Busulfan, Fludarabine and Thymoglobulin

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 47 participants Est. completion 2012-10 1 site Stand-alone
    Other conditions: Stem Cell Transplantation, Leukemia
    View official trial listing →
  • Completed NCT NCT00860457

    Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)

    Not yet reported Georgetown University 22 participants Est. completion 2012-02 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT00863330

    Laboratory-Treated Autologous Lymphocytes and Aldesleukin After Cyclophosphamide and Fludarabine in Treating Patients With Metastatic Melanoma

    Not yet reported Wake Forest University Health Sciences 14 participants Est. completion 2012-07 1 site Stand-alone
    Other conditions: Melanoma (Skin)
    View official trial listing →
  • Completed NCT NCT00864227

    Evaluating the Safety and Effectiveness of an Umbilical Cord Blood Stem Cell Transplant (BMT CTN 0604)

    Not yet reported Medical College of Wisconsin 54 participants Est. completion 2013-11 16 sites Stand-alone
    Other conditions: Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myeloid, Acute, Burkitt Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Terminated NCT NCT00915811

    Pilot Study of Reduced Intensity Haematopoietic Stem Cell Transplantation in Patients With Poor Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukaemia (AML) Utilising Conditioning With Fludarabine, Busulphan and Thymoglobulin

    Not yet reported King's College Hospital NHS Trust 20 participants Est. completion 2011-06 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute
    View official trial listing →
  • Completed NCT NCT00923364

    Pilot and Feasibility Study of Reduced-Intensity Hematopoietic Stem Cell Transplant for MonoMAC

    Not yet reported National Cancer Institute (NCI) 19 participants Est. completion 2017-02-26 1 site Stand-alone
    Other conditions: MDS, Immunodeficiency, GATA2
    View official trial listing →
  • Terminated NCT NCT00923390

    Phase 1/2 Study of Metastatic Renal Cancer Using T-Cells Transduced With a T-Cell Receptor Which Recognizes TRAIL Bound to the DR4 Receptor

    Not yet reported National Cancer Institute (NCI) 5 participants Est. completion 2012-08-24 1 site
    Other conditions: Renal Cancer, Kidney Cancer
    View official trial listing →
  • Completed NCT NCT00925821

    Lenalidomide-Adriamycin-Dexamethasone (RAD) Induction Followed by Stem Cell Transplant in Newly Diagnosed Multiple Myeloma

    Not yet reported Wuerzburg University Hospital 146 participants 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00931645

    Autologous Stem Cell Transplantation in Chronic Lymphocytic Leukemia

    Not yet reported University Hospital, Caen 241 participants Est. completion 2008-12 1 site
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Withdrawn NCT NCT00937300

    T-cell Based Immunotherapy for Head and Neck Cancer

    Not yet reported Inge Marie Svane Est. completion 2011-06 1 site
    Other conditions: Squamous Cell Carcinoma, Head and Neck Cancer
    View official trial listing →
  • Status unknown NCT NCT00946374

    Prospective Trial on Immunochemotherapy Plus Autologous Stem Cell Transplantation (SCT) and Allogenic SCT in Primary Mantle-Cell-Lymphoma

    Not yet reported Heidelberg University 20 participants Est. completion 2011-06 1 site
    Other conditions: Mantle-Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00966810

    Allogeneic Stem Cell Transplantation in CML With Partial T Cell Depletion

    Not yet reported, Not yet reported Rambam Health Care Campus 40 participants Est. completion 2011-01 1 site Stand-alone
    Other conditions: Philadelphia Chromosome-positive Chronic Myelocytic Leukemia
    View official trial listing →
  • Completed NCT NCT00997529

    Mini Allo Stem Cell Transplantation for the Treatment of Solid Tumors

    Not yet reported Beth Israel Deaconess Medical Center 14 participants Est. completion 2010-06 1 site Stand-alone
    Other conditions: Metastatic Solid Tumor
    View official trial listing →
  • Terminated NCT NCT01028716

    Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

    Not yet reported Fred Hutchinson Cancer Center 46 participants Est. completion 2021-10-07 1 site Stand-alone
    Other conditions: Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukaemia With Prior Myelodysplastic Syndrome, Acute Myeloid Leukemia in Remission, Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Inv(3)(Q21Q26.2); RPN1-EVI1, Acute Myeloid Leukemia With Multilineage Dysplasia, Acute Myeloid Leukemia With t(6;9), Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Complete Remission, B Acute Lymphoblastic Leukemia With T(1;19)(Q23;P13.3); E2A-PBX1 (TCF3-PBX1), Ph+ ALL, Burkitt Lymphoma, Childhood Acute Lymphoblastic Leukemia in Complete Remission, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Recurrent Anaplastic Large Cell Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Recurrent Follicular Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma, Secondary Acute Myeloid Leukemia, T Lymphoblastic Lymphoma, Hematopoietic Cell Transplant Recipient
    View official trial listing →
  • Terminated NCT NCT01044745

    Rituximab in Preventing Acute Graft-Versus-Host Disease in a Donor Stem Cell Transplant for Hematologic Cancer

    Not yet reported University of Nebraska 20 participants Est. completion 2017-10-10 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, de Novo Myelodysplastic Syndromes, Graft Versus Host Disease, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Adult T-cell Leukemia/Lymphoma, Stage I Chronic Lymphocytic Leukemia, Stage I Cutaneous T-cell Non-Hodgkin Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Mycosis Fungoides/Sezary Syndrome, Stage I Small Lymphocytic Lymphoma, Stage II Adult T-cell Leukemia/Lymphoma, Stage II Chronic Lymphocytic Leukemia, Stage II Cutaneous T-cell Non-Hodgkin Lymphoma, Stage II Mycosis Fungoides/Sezary Syndrome, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Chronic Lymphocytic Leukemia, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Chronic Lymphocytic Leukemia, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia, Waldenström Macroglobulinemia
    View official trial listing →
  • Status unknown NCT NCT01051115

    Dasatinib Combination for Chronic Lymphocytic Leukemia(CLL) With Refractory Disease

    Not yet reported Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) 35 participants Est. completion 2016-01 4 sites Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01085617

    Standard Chemotherapy with or Without Nelarabine or Rituximab in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia

    University College, London Est. completion 2025-02-24 Stand-alone
    Other conditions: Leukemia, Mucositis, Oral Complications
    View official trial listing →
  • Status unknown NCT NCT01087398

    Hematopoietic Stem Cell Transplantation for Malignant Infantile Osteopetrosis

    Not yet reported, Not yet reported Tehran University of Medical Sciences 10 participants Est. completion 2012-12 1 site Stand-alone
    Other conditions: Osteopetrosis
    View official trial listing →
  • Terminated NCT NCT01118013

    Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant

    Not yet reported Alliance for Clinical Trials in Oncology 6 participants Est. completion 2013-08 10 sites Stand-alone
    Other conditions: Leukemia, Lymphoma, Lymphoproliferative Disorder, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
    View official trial listing →
  • Completed NCT NCT01131169

    Busulfan, Melphalan, Fludarabine and T-Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation Followed by Post Transplantation Donor Lymphocyte Infusions

    Not yet reported Memorial Sloan Kettering Cancer Center 66 participants Est. completion 2020-05-15 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01145209

    Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 32 participants Est. completion 2023-09-15 1 site Stand-alone
    Other conditions: Small Lymphocytic Lymphoma, CLL (Chronic Lymphocytic Leukemia)
    View official trial listing →
  • Completed NCT NCT01203020

    Once Daily Targeted Intravenous (IV) Busulfex as Part of Reduced-toxicity Conditioning for Patients With Refractory Lymphomas Undergoing Allogeneic Transplantation

    Not yet reported West Virginia University 22 participants Est. completion 2021-09-27 1 site Stand-alone
    Other conditions: Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01203722

    Reduced Intensity, Partially HLA Mismatched BMT to Treat Hematologic Malignancies

    Not yet reported, Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 87 participants Est. completion 2024-05-28 1 site
    Other conditions: Hematologic Malignancies
    View official trial listing →
  • Status unknown NCT NCT01220544

    Haploidentical Transplantation With Early Adoptive Transfer of CD56+CD3- NK Cells

    Not yet reported, Not yet reported Charite University, Berlin, Germany 30 participants Est. completion 2011-10 2 sites Stand-alone
    Other conditions: Acute Myeloid Leukemias, Advanced Hematological Malignancies, Indication for Allogeneic Stem Cell Transplantation, no HLA-identical Donor Available
    View official trial listing →
  • Status unknown NCT NCT01238328

    Hematopoietic Stem Cell Transplantation for Mucopolysaccharidosis

    Not yet reported, Not yet reported Tehran University of Medical Sciences 10 participants Est. completion 2012-12 1 site Stand-alone
    Other conditions: Mucopolysaccharidosis
    View official trial listing →
  • Completed NCT NCT01247701

    Umbilical Cord Blood Transplant for Children With Myeloid Hematological Malignancies

    Not yet reported Baylor College of Medicine 16 participants Est. completion 2019-10 1 site Stand-alone
    Other conditions: Myeloid Hematological Malignancies
    View official trial listing →
  • Completed NCT NCT01256398

    Dasatinib Followed by Stem Cell Transplant in Treating Older Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    Not yet reported National Cancer Institute (NCI) 66 participants Est. completion 2021-11-15 101 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Adult B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
    View official trial listing →
  • Terminated NCT NCT01271907

    Drosophila-generated CTL

    Not yet reported National Cancer Institute (NCI) 3 participants Est. completion 2011-12-08 1 site Stand-alone
    Other conditions: Metastatic Cutaneous Melanoma
    View official trial listing →
  • Completed NCT NCT01303887

    A Trial Looking at Rituximab and Chemotherapy as a Treatment for Follicular Lymphoma in Elderly Patients

    Not yet reported University of Liverpool 680 participants Est. completion 2023-05-11 73 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT01328496

    Umbilical Cord Blood Transplantation In Patients With Hematologic Malignancies Using A Myeloablative Preparative Regimen

    Not yet reported St. Jude Children's Research Hospital 14 participants Est. completion 2016-10-31 1 site
    Other conditions: Hematologic Malignancies, Disorder Related to Transplantation, Hematopoietic Malignancy
    View official trial listing →
  • Completed NCT NCT01342289

    Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 127 participants Est. completion 2018-03 1 site Stand-alone
    Other conditions: Hodgkin's Lymphoma, Leukemia, Myelodysplastic Syndrome(MDS), Multiple Myeloma, Non Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01343043

    A Pilot Study of Genetically Engineered NY-ESO-1 Specific NY-ESO-1ᶜ²⁵⁹T in HLA-A2+ Patients With Synovial Sarcoma

    Not yet reported GlaxoSmithKline 50 participants Est. completion 2019-06-18 8 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Completed NCT NCT01349101

    A Research Study of Bone Marrow Transplantation From Unrelated or Partially Matched Related Donors

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 78 participants Est. completion 2022-12-07 1 site Stand-alone
    Other conditions: Hematological Malignancies
    View official trial listing →
  • Terminated NCT NCT01369875

    Modified Tumor Infiltrating Lymphocytes for Metastatic Melanoma

    Not yet reported National Cancer Institute (NCI) 2 participants Est. completion 2012-02-14 1 site Stand-alone
    Other conditions: Metastatic Melanoma, Skin Cancer
    View official trial listing →
  • Completed NCT NCT01385423

    Haploidentical Donor Natural Killer Cell Infusion With IL-15 in Acute Myelogenous Leukemia (AML)

    Not yet reported Masonic Cancer Center, University of Minnesota 26 participants Est. completion 2015-03 1 site Stand-alone
    Other conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT01499147

    Fludarabine Based Conditioning for Allogeneic Transplantation for Advanced Hematologic Malignancies

    Not yet reported University of Illinois at Chicago 100 participants Est. completion 2013-05 1 site
    Other conditions: Acute Myeloid Leukemia, Acute Leukemia, Chronic Myelogenous Leukemia, Malignant Lymphoma, Hodgkin's Disease, Multiple Myeloma, Lymphocytic Leukemia, Myeloproliferative Disorder, Polycythemia Vera, Myelofibrosis, Aplastic Anemia
    View official trial listing →
  • Completed NCT NCT01527045

    Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies

    Not yet reported Fred Hutchinson Cancer Center 47 participants Est. completion 2019-04 2 sites Stand-alone
    Other conditions: Aggressive Non-Hodgkin Lymphoma, Blasts Under 5 Percent of Bone Marrow Nucleated Cells, Chronic Lymphocytic Leukemia, Loss of Chromosome 17p, Myelodysplastic/Myeloproliferative Neoplasm, Non-Hodgkin Lymphoma, Prolymphocytic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Aggressive Adult Non-Hodgkin Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT01564784

    A Study Of Inotuzumab Ozogamicin Versus Investigator's Choice Of Chemotherapy In Patients With Relapsed Or Refractory Acute Lymphoblastic Leukemia

    Not yet reported Pfizer 326 participants Est. completion 2017-01-04 198 sites
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT01585428

    Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Human Papillomavirus-Associated Cancers

    Not yet reported National Cancer Institute (NCI) 29 participants Est. completion 2016-08-01 1 site Stand-alone
    Other conditions: Cervical Cancer, Oropharyngeal Cancer, Vaginal Cancer, Anal Cancer, Penile Cancer
    View official trial listing →
  • Completed NCT NCT01593696

    Anti-CD19 White Blood Cells for Children and Young Adults With B Cell Leukemia or Lymphoma

    Not yet reported National Cancer Institute (NCI) 53 participants Est. completion 2017-10-02 1 site Stand-alone
    Other conditions: ALL, B Cell Lymphoma, Leukemia, Large Cell Lymphoma, Non-Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT01640301

    Laboratory-Treated T Cells in Treating Patients With High-Risk Relapsed Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelogenous Leukemia Previously Treated With Donor Stem Cell Transplant

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 47 participants Est. completion 2020-03-20 1 site Stand-alone
    Other conditions: Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Donor, Hematopoietic Cell Transplant Recipient, HLA-A*0201 Positive Cells Present, Recurrent Acute Myeloid Leukemia
    View official trial listing →
  • Withdrawn NCT NCT01652014

    Single or Double Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Hematologic Malignancies

    Not yet reported University of Medicine and Dentistry of New Jersey Est. completion 2017-01 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Blastic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, de Novo Myelodysplastic Syndromes, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Acute Myeloid Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, T-cell Large Granular Lymphocyte Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT01653717

    CD19-specific T-cell for Chronic Lymphocytic Leukemia (CLL)

    Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2017-08-07 1 site Stand-alone
    Other conditions: Advanced Cancers, Leukemia
    View official trial listing →
  • Completed NCT NCT01658319

    Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies

    Not yet reported Case Comprehensive Cancer Center 20 participants Est. completion 2015-05 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Peripheral T-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Chronic Lymphocytic Leukemia, Testicular Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Active, not recruiting NCT NCT01659606

    Radiation- and Alkylator-free Bone Marrow Transplantation Regimen for Patients With Dyskeratosis Congenita

    Not yet reported Boston Children's Hospital 40 participants Est. completion 2034-12 13 sites Stand-alone
    Other conditions: Dyskeratosis Congenita, Hoyeraal Hreidarsson Syndrome, Revesz Syndrome, Aplastic Anemia
    View official trial listing →
  • Terminated NCT NCT01701323

    Expanded Cord Blood Cell Infusion Following Combination Chemotherapy in Younger Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported Nohla Therapeutics, Inc. 7 participants Est. completion 2018-05-10 2 sites Stand-alone
    Other conditions: Acute Leukemia of Ambiguous Lineage, Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT01745913

    Randomized HaploCord Blood Transplantation vs. Double Umbilical Cord Blood Transplantation for Hematologic Malignancies

    Not yet reported Weill Medical College of Cornell University 2 participants Est. completion 2015-04-29 1 site Stand-alone
    Other conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01751997

    Family-mismatched/Haploidentical Donors Versus Matched Unrelated Donors

    Not yet reported, Not yet reported Byung-Sik Cho 116 participants Est. completion 2019-12-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01760655

    Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 62 participants Est. completion 2022-12-05 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Leukemia, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT01773395

    GVAX vs. Placebo for MDS/AML After Allo HSCT

    Not yet reported Dana-Farber Cancer Institute 123 participants Est. completion 2021-11-24 4 sites
    Other conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01785810

    Phase II Maraviroc for GVHD Prevention

    Not yet reported Abramson Cancer Center at Penn Medicine 37 participants Est. completion 2018-07-12 1 site Stand-alone
    Other conditions: Hematologic Malignancy
    View official trial listing →
  • Completed NCT NCT01787474

    Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2021-06-17 1 site Stand-alone
    Other conditions: Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT01814046

    Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

    Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2017-05-31 1 site Stand-alone
    Other conditions: Metastatic Ocular Melanoma, Metastatic Uveal Melanoma
    View official trial listing →
  • Status unknown NCT NCT01946373

    T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

    Not yet reported Karolinska University Hospital 20 participants Est. completion 2025-12 1 site Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT01955460

    Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma

    Not yet reported M.D. Anderson Cancer Center 34 participants Est. completion 2027-10-30 1 site Stand-alone
    Other conditions: Metastatic Melanoma, Stage III Cutaneous Melanoma AJCC v7, Stage IIIA Cutaneous Melanoma AJCC v7, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT01967823

    T Cell Receptor Immunotherapy Targeting NY-ESO-1 for Patients With NY-ESO-1 Expressing Cancer

    Not yet reported National Cancer Institute (NCI) 11 participants Est. completion 2020-04-06 1 site Stand-alone
    Other conditions: Melanoma, Meningioma, Breast Cancer, Non-Small Cell Lung Cancer, Hepatocellular Cancer
    View official trial listing →
  • Status unknown NCT NCT01983761

    Study of ASC-101 in Patients With Hematologic Malignancies Who Receive Dual-cord Umbilical Cord Blood Transplantation

    Not yet reported, Not yet reported Targazyme, Inc. 25 participants 4 sites Stand-alone
    Other conditions: Blood And Marrow Transplantation, Leukemia, Lymphoma, Transplantation Infection, Myelodysplastic Syndrome (MDS), Non-Hodgkin's Lymphoma (NHL), Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT01998633

    Reduced Intensity Conditioning for Hemophagocytic Syndromes or Selected Primary Immune Deficiencies (BMT CTN 1204)

    Not yet reported Medical College of Wisconsin 47 participants Est. completion 2016-12 22 sites Stand-alone
    Other conditions: Hemophagocytic Lymphohistiocytosis, Chronic Active Epstein-Barr Virus Infection, Chronic Granulomatous Disease, HIGM-1, Leukocyte Adhesion Deficiency, IPEX
    View official trial listing →
  • Completed NCT NCT02039726

    (QuANTUM-R): An Open-label Study of Quizartinib Monotherapy vs. Salvage Chemotherapy in Acute Myeloid Leukemia (AML) Subjects Who Are FLT3-ITD Positive

    Not yet reported Daiichi Sankyo 367 participants Est. completion 2020-09-08 131 sites
    Other conditions: AML
    View official trial listing →
  • Withdrawn NCT NCT02053545

    Haplo-identical SCT for High Risk (HR) Hematologic Malignancies w/Post-Transplant In-Vivo T-cell Depletion

    Not yet reported, Not yet reported Ann & Robert H Lurie Children's Hospital of Chicago Est. completion 2017-05-11 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma, MDS
    View official trial listing →
  • Terminated NCT NCT02057770

    Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported Washington University School of Medicine 25 participants Est. completion 2018-03-23 1 site Stand-alone
    Other conditions: Leukemia, Myeloid, Acute
    View official trial listing →
  • Active, not recruiting NCT NCT02065362

    TGF-beta Resistant Cytotoxic T-lymphocytes in Treatment of EBV-positive Nasopharyngeal Carcinoma / RESIST-NPC

    Not yet reported Baylor College of Medicine 14 participants Est. completion 2033-02 1 site Stand-alone
    Other conditions: EBV-positive Nasopharyngeal Carcinoma
    View official trial listing →
  • Completed NCT NCT02084563

    Study of Molecular and Genetic Abnormalities in Patients With Myeloid Neoplasms

    Not yet reported Hospital Israelita Albert Einstein 455 participants Est. completion 2016-11 1 site
    Other conditions: Acute Myeloid Leukemia, Myeloproliferative Neoplasms, Myelodysplastic Syndromes, Myeloproliferative/Myelodysplastic Neoplasm
    View official trial listing →
  • Completed NCT NCT02128945

    Dosimetry and Biodistribution of [18F]-Fludarabine in Lymphoid Malignancies

    Not yet reported University Hospital, Caen 10 participants Est. completion 2016-05 1 site Stand-alone
    Other conditions: Untreated B-Chronic Lymphocytic Leukemia or Diffuse Large B Cells Lymphoma Patients
    View official trial listing →
  • Active, not recruiting NCT NCT02153580

    Cellular Immunotherapy Following Chemotherapy in Treating Patients With Recurrent Non-Hodgkin Lymphomas, Chronic Lymphocytic Leukemia, or B-Cell Prolymphocytic Leukemia

    Not yet reported City of Hope Medical Center 37 participants Est. completion 2026-09-02 1 site Stand-alone
    Other conditions: B-Cell Lymphoma, Unclassifiable, With Features Intermediate Between Diffuse Large B-Cell Lymphoma and Classic Hodgkin Lymphoma, B-Cell Prolymphocytic Leukemia, High Grade B-Cell Lymphoma, Not Otherwise Specified, Post-Transplant Lymphoproliferative Disorder, Recurrent Adult Burkitt Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Hairy Cell Leukemia, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT02167958

    Nonmyeloablative Hematopoietic Cell Transplantation (HCT) for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors: A Pilot Trial of Peripheral Blood Stem Cells (PBSC) as the Donor Source

    Not yet reported Rafic Farah, MD 28 participants Est. completion 2019-09-21 1 site Stand-alone
    Other conditions: Leukemia, MDS, Myelofibrosis, Lymphoma
    View official trial listing →
  • Completed NCT NCT02169791

    Nonmyeloablative Haploidentical Transplant Followed by MLN9708

    Not yet reported Northside Hospital, Inc. 29 participants Est. completion 2020-07-28 1 site Stand-alone
    Other conditions: Acute Leukemia, Chronic Leukemia, Myelodysplastic Syndrome, Lymphomas, Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT02171104

    MT2013-31: Allo HCT for Metabolic Disorders and Severe Osteopetrosis

    Not yet reported Masonic Cancer Center, University of Minnesota 149 participants Est. completion 2029-07-14 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Mucopolysaccharidosis Disorders, Hurler Syndrome, Hunter Syndrome, Maroteaux Lamy Syndrome, Sly Syndrome, Alpha-Mannosidosis, Fucosidosis, Glycoprotein Metabolic Disorders, Sphingolipidoses, Recessive Leukodystrophies, Globoid Cell Leukodystrophy, Metachromatic Leukodystrophy, Niemann-Pick B, Niemann-Pick C Subtype 2, Sphingomyelin Deficiency, Peroxisomal Disorders, Adrenoleukodystrophy With Cerebral Involvement, Zellweger Syndrome, Neonatal Adrenoleukodystrophy, Infantile Refsum Disease, Acyl-CoA Oxidase Deficiency, D-Bifunctional Enzyme Deficiency, Multifunctional Enzyme Deficiency, Alpha-methylacyl-CoA Racmase Deficiency, Mitochondrial Neurogastrointestingal Encephalopathy, Severe Osteopetrosis, Hereditary Leukoencephalopathy With Axonal Spheroids (HDLS; CSF1R Mutation), Inherited Metabolic Disorders
    View official trial listing →
  • Withdrawn NCT NCT02194374

    Autologous ROR1R-CAR-T Cells for Chronic Lymphocytic Leukemia (CLL)

    Not yet reported M.D. Anderson Cancer Center Est. completion 2017-06 Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT02224872

    Transplantation of Partially Mismatched Related or Matched Unrelated Bone Marrow for Patients With Refractory Severe Aplastic Anemia

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 18 participants Est. completion 2021-12 2 sites Stand-alone
    Other conditions: Severe Aplastic Anemia, Bone Marrow Failure Syndromes
    View official trial listing →
  • Active, not recruiting NCT NCT02250937

    Venetoclax and Sequential Busulfan, Cladribine, and Fludarabine Phosphate Before Donor Stem Cell Transplant in Treating Patients With Acute Myelogenous Leukemia or Myelodysplastic Syndrome

    Not yet reported M.D. Anderson Cancer Center 116 participants Est. completion 2027-10-31 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT02294552

    Post-transplantation Cyclophosphamide as GVHD Prophylaxis After HSCT

    Not yet reported Ivan S Moiseev 200 participants Est. completion 2017-11 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Lymphoma, Myelodysplastic Syndromes, Chronic Lymphocytic Leukemia, Immune System Diseases
    View official trial listing →
  • Completed NCT NCT02348216

    Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported Kite, A Gilead Company 307 participants Est. completion 2023-07-27 36 sites Stand-alone
    Other conditions: Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed Diffuse Large B-Cell Lymphoma, Transformed Follicular Lymphoma (TFL), Primary Mediastinal B-cell Lymphoma (PMBCL), High Grade B-cell Lymphoma (HGBCL)
    View official trial listing →
  • Completed NCT NCT02414945

    TILs & Low-Dose IL-2 Therapy Following Cyclophosphamide and Fludarabine in Pleural Mesothelioma Patients

    Not yet reported, Not yet reported University Health Network, Toronto 9 participants Est. completion 2020-10 1 site Stand-alone
    Other conditions: Pleural Mesothelioma
    View official trial listing →
  • Completed NCT NCT02421939

    A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

    Not yet reported Astellas Pharma Global Development, Inc. 371 participants Est. completion 2025-02-25 126 sites
    Other conditions: Leukemia, Acute Myeloid (AML)
    View official trial listing →
  • Completed NCT NCT02461121

    HLA-mismatched MST vs HLA-matched NST for AML in Intermediate-risk

    Not yet reported The Affiliated Hospital of the Chinese Academy of Military Medical Sciences 156 participants Est. completion 2013-05 1 site
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT02483325

    Study Evaluating the Efficacy of Allogeneic Transplant Conditioning With Adaptive Dose Busulfan Intravenous (Busilvex®) in Patients at High Risk of Carrying Blood Diseases

    Not yet reported Institut Paoli-Calmettes 33 participants Est. completion 2020-03 1 site
    Other conditions: Hematological Diseases
    View official trial listing →
  • Withdrawn NCT NCT02489266

    In Vivo Persistence of Adoptively-Transferred TIL Cultured With Akti in People With Metastatic Melanoma

    Not yet reported National Cancer Institute (NCI) Est. completion 2016-06-29 Stand-alone
    Other conditions: Metastatic Melanoma
    View official trial listing →
  • Completed NCT NCT02500576

    Pembrolizumab, Standard Chemotherapy, Tumor Infiltrating Lymphocytes, and High- or Low-Dose Aldesleukin in Treating Patients With Metastatic Melanoma

    Not yet reported M.D. Anderson Cancer Center 18 participants Est. completion 2022-10-12 1 site Stand-alone
    Other conditions: Metastatic Melanoma, Stage IIIB Cutaneous Melanoma AJCC v7, Stage IIIC Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7
    View official trial listing →
  • Terminated NCT NCT02512679

    Related Hematopoietic Stem Cell Transplantation (HSCT) for Genetic Diseases of Blood Cells

    Not yet reported Children's Hospital Los Angeles 20 participants Est. completion 2014-02
    Other conditions: Stem Cell Transplantation, Bone Marrow Transplantation, Peripheral Blood Stem Cell Transplantation, Allogeneic Transplantation, Genetic Diseases, Thalassemia, Pediatrics, Diamond-Blackfan Anemia, Combined Immune Deficiency, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, X-linked Lymphoproliferative Disease, Metabolic Diseases
    View official trial listing →
  • Active, not recruiting NCT NCT02514083

    A Phase II Study Using Ibrutinib and Short-Course Fludarabine in Treatment-Naive CLL

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 29 participants Est. completion 2034-10-23 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT02520895

    Immunological Repertoire in Patients With Lymphoma and Chronic Lymphocytic Leukemia

    Hospices Civils de Lyon 98 participants Est. completion 2013-10 1 site
    Other conditions: LYMPHOMA
    View official trial listing →
  • Completed NCT NCT02601313

    Study of Brexucabtagene Autoleucel (KTE-X19) in Participants With Relapsed/Refractory Mantle Cell Lymphoma (Cohort 1 and Cohort 2)

    Not yet reported Kite, A Gilead Company 105 participants Est. completion 2023-09-22 32 sites Stand-alone
    Other conditions: Relapsed/Refractory Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02614066

    A Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel (KTE-X19) in Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ZUMA-3)

    Not yet reported, Not yet reported Kite, A Gilead Company 125 participants Est. completion 2023-11-03 33 sites Stand-alone
    Other conditions: Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT02626338

    Pilot Study of Crenolanib Combined With Standard Salvage Chemotherapy in Subjects With R/R AML

    Not yet reported, Not yet reported Arog Pharmaceuticals, Inc. 16 participants Est. completion 2018-02 4 sites Stand-alone
    Other conditions: Relapsed/Refractory Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Active, not recruiting NCT NCT02629809

    Ibrutinib, Fludarabine Phosphate, Cyclophosphamide, and Obinutuzumab in Treating Patients With Chronic Lymphocytic Leukemia

    Not yet reported M.D. Anderson Cancer Center 81 participants Est. completion 2028-03-31 1 site Stand-alone
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT02666898

    Phase II Trial GA101 Inbrutinib B CLL

    Not yet reported French Innovative Leukemia Organisation 135 participants Est. completion 2023-09 1 site Stand-alone
    Other conditions: Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Terminated NCT NCT02706405

    JCAR014 and Durvalumab in Treating Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported Fred Hutchinson Cancer Center 30 participants Est. completion 2021-05-28 1 site Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC, BCL2, and BCL6 Rearrangements, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT02724163

    International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia

    Not yet reported University of Birmingham 700 participants Est. completion 2032-12 68 sites Stand-alone
    Other conditions: Acute Myeloid Leukaemia
    View official trial listing →
  • Terminated NCT NCT02737384

    Hematopoietic Stem Cells Transplantation in Children With Combined Immunodeficiency (CID)

    Not yet reported Assistance Publique - Hôpitaux de Paris 4 participants Est. completion 2017-10-26 1 site Stand-alone
    Other conditions: Combined Immunodeficiencies
    View official trial listing →
  • Completed NCT NCT02788201

    Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

    Not yet reported National Cancer Institute (NCI) 8 participants Est. completion 2019-10-23 1 site Stand-alone
    Other conditions: Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT02790515

    Provision of TCRγδ T Cells and Memory T Cells Plus Selected Use of Blinatumomab in Naïve T-cell Depleted Haploidentical Donor Hematopoietic Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation

    Not yet reported St. Jude Children's Research Hospital 170 participants Est. completion 2026-07-01 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myeloid Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
    View official trial listing →
  • Completed NCT NCT02799147

    GVHD Prophylaxis With Post-transplantation Bendamustine in Refractory Leukemia

    Not yet reported, Not yet reported St. Petersburg State Pavlov Medical University 27 participants Est. completion 2020-11 1 site Stand-alone
    Other conditions: Leukemia, Acute Lymphoblastic, Acute Myeloid Leukemia, Mixed-Lineage Acute Leukemias
    View official trial listing →
  • Status unknown NCT NCT02809092

    Interleukin-21 (IL-21)- Expanded Natural Killer Cells for Induction of Acute Myeloid Leukemia

    Not yet reported, Not yet reported Hospital de Clinicas de Porto Alegre 30 participants Est. completion 2020-09 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT02880293

    Haploidentical (Half-matched) Related Donor Stem Cell Transplantation Using Killer Immunoglobulin-like Receptors in Addition to Normal Selection Factors to Determine the Best Donor

    Not yet reported Memorial Sloan Kettering Cancer Center 44 participants Est. completion 2023-11-20 1 site Stand-alone
    Other conditions: Hematologic Malignancy
    View official trial listing →
  • Completed NCT NCT02881086

    Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment

    Not yet reported Goethe University 1023 participants Est. completion 2024-12 1 site
    Other conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
    View official trial listing →
  • Status unknown NCT NCT02894645

    Malaysia-Singapore Acute Lymphoblastic Leukemia 2010 Study

    Not yet reported National University Hospital, Singapore 500 participants 4 sites
    Other conditions: Acute Lymphoblastic Leukemia (ALL)
    View official trial listing →
  • Status unknown NCT NCT02933775

    CD19-redirected Autologous Cells (CAR-CD19 T Cells)

    Not yet reported RenJi Hospital 45 participants Est. completion 2020-01 1 site Stand-alone
    Other conditions: CD19 Positive Malignant B-cell Leukemia and Lymphoma
    View official trial listing →
  • Status unknown NCT NCT02937844

    Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme

    Not yet reported Beijing Sanbo Brain Hospital 20 participants Est. completion 2019-07 1 site Stand-alone
    Other conditions: Glioblastoma Multiforme
    View official trial listing →
  • Terminated NCT NCT02991898

    Adoptive TReg Cell for Suppression of aGVHD After UCB HSCT for Heme Malignancies

    Not yet reported Masonic Cancer Center, University of Minnesota 3 participants Est. completion 2019-06-20 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Burkitt Lymphoma, Natural Killer Cell Malignancies, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Large-cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Marginal Zone B-Cell Lymphoma, Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle-Cell Lymphoma, Prolymphocytic Leukemia, Hodgkin Lymphoma, Multiple Myeloma, Acute Myelogenous Leukemia, Biphenotypic Leukemia, Undifferentiated Leukemia
    View official trial listing →
  • Status unknown NCT NCT03016988

    The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

    Not yet reported Tingbo Liu 50 participants Est. completion 2020-12
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03068819

    Cytokine Induced Memory-like NK Cell Adoptive Therapy for Relapsed AML After Allogeneic Hematopoietic Cell Transplant

    Not yet reported, Not yet reported Washington University School of Medicine 62 participants Est. completion 2025-06-15 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03079089

    Sequential Conditioning in Haploidentical Transplantation for Hematopoietic Stem Cells in Patients With Relapsed or Refractory Lymphoid Hematological Disorders

    Not yet reported Association for Training, Education, and Research in Hematology, Immunology, and Transplantation 40 participants Est. completion 2023-09-11 1 site
    Other conditions: Refractory or Relapsed Lymphoid Haemopathy
    View official trial listing →
  • Status unknown NCT NCT03084380

    Anti-GPC3 CAR-T for Treating GPC3-positive Advanced Hepatocellular Carcinoma (HCC)

    Not yet reported, Not yet reported Xinqiao Hospital of Chongqing 20 participants Est. completion 2020-05-31 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma
    View official trial listing →
  • Status unknown NCT NCT03093168

    BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

    Not yet reported The Second Affiliated Hospital of Henan University of Traditional Chinese Medicine 10 participants Est. completion 2020-02 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03105336

    A Study of Axicabtagene Ciloleucel in Participants With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma

    Not yet reported Kite, A Gilead Company 159 participants Est. completion 2024-12-20 19 sites Stand-alone
    Other conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Indolent Non-Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT03139370

    Safety and Efficacy of MAGE-A3/A6 T Cell Receptor Engineered T Cells (KITE-718) in HLA-DPB1*04:01 Positive Adults With Advanced Cancers

    Not yet reported Kite, A Gilead Company 16 participants Est. completion 2023-06-04 12 sites Stand-alone
    Other conditions: Solid Tumor
    View official trial listing →
  • Status unknown NCT NCT03142646

    Safety and Efficacy Evaluation of IM19 CAR-T Cells

    Not yet reported, Not yet reported Beijing Immunochina Medical Science & Technology Co., Ltd. 60 participants Est. completion 2018-10-01 2 sites Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT03159585

    To Evaluate the Efficacy of NY-ESO-1-specific T Cell Receptor Affinity Enhancing Specific T Cell in Solid Tumors

    Not yet reported Zhujiang Hospital 6 participants Est. completion 2019-06-04 1 site Stand-alone
    Other conditions: Liver Cancer Stage IV, Gastric Cancer Stage IV, Esophageal Cancer, Stage IV, Bone and Soft Tissue Tumors, Breast Cancer Stage IV, Bladder Carcinoma Stage IV, Prostate Carcinoma Stage IV, Thyroid Cancer Stage IV, Ovarian Cancer Stage IV, Solid Tumor
    View official trial listing →
  • Completed NCT NCT03159702

    Propylene Glycol-Free Melphalan HCl (EVOMELA®) in Combination With Fludarabine and Total Body Irradiation Based Reduced Intensity Conditioning for Haploidentical Transplantation

    Not yet reported Medical College of Wisconsin 43 participants Est. completion 2025-12-08 1 site Stand-alone
    Other conditions: Hematological Malignancy, Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03170141

    Immunogene-modified T (IgT) Cells Against Glioblastoma Multiforme

    Not yet reported Shenzhen Geno-Immune Medical Institute 30 participants Est. completion 2026-07-31 1 site Stand-alone
    Other conditions: Glioblastoma Multiforme of Brain, Brain Cancer
    View official trial listing →
  • Status unknown NCT NCT03191773

    A Study of Anti-CD19 CAR-T Cell Immunotherapy for Refractory /Relapsed B Cell Malignancies

    Not yet reported, Not yet reported Second Affiliated Hospital of Guangzhou Medical University 100 participants Est. completion 2020-12-31 5 sites Stand-alone
    Other conditions: Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
    View official trial listing →
  • Suspended NCT NCT03229876

    Safety and Efficacy Evaluation of CD19-UCART

    Not yet reported Bioray Laboratories 20 participants Est. completion 2023-12-30 2 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia (ALL), Non Hodgkin Lymphoma (NHL)
    View official trial listing →
  • Status unknown NCT NCT03246178

    Haploidentical Transplantation in Severe Aplastic Anemia

    Not yet reported Wu Xiaoxiong 60 participants Est. completion 2020-12-01 1 site Stand-alone
    Other conditions: Severe Aplastic Anemia
    View official trial listing →
  • Active, not recruiting NCT NCT03247088

    Sorafenib, Busulfan and Fludarabine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia Undergoing Donor Stem Cell Transplant

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 74 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03270748

    Post Transplant High-Dose Cy as GvHD Prophylaxis in 1 HLA Mismatched Unrelated HSCT for Myeloid Malignancies

    Not yet reported Gruppo Italiano Trapianto di Midollo Osseo 78 participants Est. completion 2022-11-20 33 sites Stand-alone
    Other conditions: Myeloid Malignancies
    View official trial listing →
  • Active, not recruiting NCT NCT03277729

    A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 53 participants Est. completion 2039-03 1 site Stand-alone
    Other conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Follicular Lymphoma, Recurrent Lymphoplasmacytic Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory Follicular Lymphoma, Refractory Lymphoplasmacytic Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Transformed Non-Hodgkin Lymphoma, Recurrent Transformed B-Cell Non-Hodgkin Lymphoma, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Marginal Zone Lymphoma, Refractory Transformed B-Cell Non-Hodgkin Lymphoma, Refractory Transformed Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Small Lymphocytic Lymphoma, Recurrent Central Nervous System Lymphoma, Refractory Central Nervous System Lymphoma
    View official trial listing →
  • Terminated NCT NCT03303950

    Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis

    Not yet reported University of Utah 6 participants Est. completion 2020-02-19 1 site Stand-alone
    Other conditions: Anemia, ASXL1 Gene Mutation, EZH2 Gene Mutation, IDH1 Gene Mutation, IDH2 Gene Mutation, Plasma Cell Myeloma, Primary Myelofibrosis, Recurrent Plasma Cell Myeloma, Secondary Myelofibrosis, Thrombocytopenia
    View official trial listing →
  • Terminated NCT NCT03318861

    Study to Evaluate the Safety and Efficacy of KITE-585 in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported Kite, A Gilead Company 17 participants Est. completion 2022-09-16 9 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT03324243

    A Study of Crenolanib With Fludarabine and Cytarabine in Pediatric Patients With Relapsed/Refractory FLT3-Mutated Acute Myeloid Leukemia

    Not yet reported Arog Pharmaceuticals, Inc. Est. completion 2020-12 Stand-alone
    Other conditions: Relapsed/Refractory FLT3-mutated AML
    View official trial listing →
  • Status unknown NCT NCT03344367

    Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported Peking University 20 participants Est. completion 2022-03 1 site Stand-alone
    Other conditions: Non Hodgkin Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03355859

    Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported Zhao Weili 10 participants Est. completion 2022-03 1 site Stand-alone
    Other conditions: Non Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT03393611

    CPX-351 Salvage Therapy Followed by Haplo-Cord Transplant for Relapsed/Refractory Leukemia or Myelodysplastic Syndrome

    Not yet reported Weill Medical College of Cornell University 14 participants Est. completion 2021-11-18 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Leukemia, Relapsed Adult Acute Myeloid, Myelodysplastic Syndromes, Previously Treated
    View official trial listing →
  • Status unknown NCT NCT03412409

    RIC Regimen for Elderly or High Comorbidity Burden Patients Receiving Haplo-HSCT

    Not yet reported Peking University People's Hospital 50 participants Est. completion 2025-09-01 1 site Stand-alone
    Other conditions: Acute Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT03430011

    Study Evaluating the Safety and Efficacy of JCARH125 in Subjects With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Juno Therapeutics, a Subsidiary of Celgene 165 participants Est. completion 2023-03-30 20 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03455504

    Venetoclax Add in Combination With Fludarabine, Cyratabine and Idarubicine in Induction for Acute Myelid Leukemia

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 124 participants Est. completion 2026-07-15 22 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03467516

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma

    Not yet reported Udai Kammula 34 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Uveal Neoplasms, Melanoma, Uveal
    View official trial listing →
  • Suspended NCT NCT03494569

    Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

    Not yet reported City of Hope Medical Center 36 participants Est. completion 2026-09-08 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia, Acute Myeloid Leukemia in Remission, Hematopoietic Cell Transplantation Recipient, Minimal Residual Disease, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03513328

    Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation

    Not yet reported, Not yet reported University of Florida 6 participants Est. completion 2023-02-19 1 site Stand-alone
    Other conditions: Bone Marrow Failure Syndrome, Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Acquired Neutropenia in Newborn, Acquired Anemia Hemolytic, Acquired Thrombocytopenia, Hemophagocytic Lymphohistiocytoses, Wiskott-Aldrich Syndrome, Chronic Granulomatous Disease, Common Variable Immunodeficiency, X-linked Lymphoproliferative Disease, Severe Combined Immunodeficiency, Hurler Syndrome, Mannosidosis, Adrenoleukodystrophy
    View official trial listing →
  • Terminated NCT NCT03526185

    A Pilot Study Using Short-Term Cultured Anti-Tumor Autologous Lymphocytes

    Not yet reported Yale University 6 participants Est. completion 2020-12-01 1 site Stand-alone
    Other conditions: Metastatic Melanoma
    View official trial listing →
  • Status unknown NCT NCT03540303

    Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma

    Not yet reported Henan Cancer Hospital 15 participants Est. completion 2020-04-30 1 site Stand-alone
    Other conditions: Relapsed Non Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT03570892

    Tisagenlecleucel in Adult Patients With Aggressive B-cell Non-Hodgkin Lymphoma

    Not yet reported Novartis Pharmaceuticals 330 participants Est. completion 2026-02-03 67 sites Stand-alone
    Other conditions: Non-Hodgkin Lymphoma
    View official trial listing →
  • No Longer Available NCT NCT03594162

    Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch

    UNC Lineberger Comprehensive Cancer Center 1 site
    Other conditions: Acute Lymphoblastic Leukemia, Immune System Diseases, Immunoproliferative Disorders
    View official trial listing →
  • Active, not recruiting NCT NCT03597594

    Haplocompatible Transplant Using TCRα/β Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID)

    Not yet reported, Not yet reported St. Jude Children's Research Hospital 4 participants Est. completion 2028-07-01 1 site
    Other conditions: Severe Combined Immunodeficiency
    View official trial listing →
  • Active, not recruiting NCT NCT03613532

    Venetoclax Added to Fludarabine + Busulfan Prior to Transplant and to Maintenance Therapy for AML, MDS, and MDS/MPN

    Not yet reported Jacqueline Garcia, MD 102 participants Est. completion 2030-03-05 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Chronic Myelomonocytic Leukemia (CMML), MDS/Myeloproliferative Neoplasm-unclassifiable (MDS/MPN-unclassifiable), Hematopoietic Stem Cell Transplant
    View official trial listing →
  • Terminated NCT NCT03616470

    Study to Determine the Efficacy of Uproleselan (GMI-1271) in Combination With Chemotherapy to Treat Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported GlycoMimetics Incorporated 388 participants Est. completion 2024-03-31 70 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT03661515

    Selinexor (KPT-330) Plus FLAG-Ida for the Treatment of Relapsing/Refractory AML

    Not yet reported PETHEMA Foundation 16 participants Est. completion 2019-10-15 4 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT03672851

    Study Evaluating Safety and Efficacy of CAR-T Cells Targeting CD123 in Patients With Acute Leukemia

    Not yet reported Second Affiliated Hospital of Xi'an Jiaotong University 2 participants Est. completion 2019-07-31 1 site Stand-alone
    Other conditions: Acute Leukemia, Acute Leukemia in Relapse, Acute Myeloid Leukemia, Relapsed or Refractory Acute Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03690011

    Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells

    Not yet reported Baylor College of Medicine 45 participants Est. completion 2041-03-31 2 sites Stand-alone
    Other conditions: T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma, T-cell Acute Lymphoblastic Leukemia
    View official trial listing →
  • Status unknown NCT NCT03692663

    Study of Anti-PSMA CAR NK Cell (TABP EIC) in Metastatic Castration-Resistant Prostate Cancer

    Not yet reported Allife Medical Science and Technology Co., Ltd. 9 participants Est. completion 2024-06 1 site Stand-alone
    Other conditions: Metastatic Castration-resistant Prostate Cancer
    View official trial listing →
  • Terminated NCT NCT03704298

    Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Adults With Refractory Large B-cell Lymphoma

    Not yet reported Kite, A Gilead Company 15 participants Est. completion 2022-12-15 5 sites Stand-alone
    Other conditions: Relapsed/Refractory Large B-cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03706547

    Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM

    Not yet reported Peng Liu 20 participants Est. completion 2021-12 1 site Stand-alone
    Other conditions: Multiple Myeloma in Relapse, Multiple Myeloma Progression
    View official trial listing →
  • Suspended NCT NCT03710421

    CS1-CAR T Therapy Following Chemotherapy in Treating Patients With Relapsed or Refractory CS1 Positive Multiple Myeloma

    Not yet reported City of Hope Medical Center 30 participants Est. completion 2027-02-23 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT03743246

    A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL)

    Not yet reported, Not yet reported Celgene 21 participants Est. completion 2024-01-26 19 sites Stand-alone
    Other conditions: Precursor Cell Lymphoblastic Leukemia-Lymphoma, Lymphoma, Non-Hodgkin
    View official trial listing →
  • Status unknown NCT NCT03767725

    Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

    Not yet reported Shenzhen Second People's Hospital 10 participants Est. completion 2021-09-01 1 site Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Status unknown NCT NCT03799913

    MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

    Not yet reported Zhejiang University 20 participants Est. completion 2022-04 1 site Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03801083

    Adoptive Transfer of Tumor Infiltrating Lymphocytes for Biliary Tract Cancers

    Not yet reported Udai Kammula 4 participants Est. completion 2031-01-31 1 site Stand-alone
    Other conditions: Biliary Tract Cancer, Cholangiocarcinoma, Biliary Tract Neoplasms
    View official trial listing →
  • Status unknown NCT NCT03814447

    The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

    Not yet reported Shanghai 6th People's Hospital 10 participants Est. completion 2023-01 1 site Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03849651

    TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies

    Not yet reported St. Jude Children's Research Hospital 69 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), NK-Cell Leukemia, Hodgkin Lymphoma, Non Hodgkin Lymphoma (NHL), Juvenile Myelomonocytic Leukemia (JMML), Chronic Myeloid Leukemia (CML)
    View official trial listing →
  • Completed NCT NCT03852498

    A Clinical Study to Assess the Efficacy and Safety of Gene Therapy for the Treatment of Cerebral Adrenoleukodystrophy (CALD)

    Not yet reported Genetix Biotherapeutics Inc. 35 participants Est. completion 2023-07-24 8 sites Stand-alone
    Other conditions: Cerebral Adrenoleukodystrophy (CALD)
    View official trial listing →
  • Terminated NCT NCT03860844

    Isatuximab in Combination With Chemotherapy in Pediatric Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia or Acute Myeloid Leukemia

    Not yet reported Sanofi 67 participants Est. completion 2023-05-26 41 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03873805

    PSCA-CAR T Cells in Treating Patients With PSCA+ Metastatic Castration Resistant Prostate Cancer

    Not yet reported City of Hope Medical Center 14 participants Est. completion 2027-03-18 1 site Stand-alone
    Other conditions: Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT03881774

    Cord Blood Derived CAR-T Cells in Refractory/Relapsed B Cell Malignancies

    Not yet reported Henan Cancer Hospital 20 participants Est. completion 2022-01-31 2 sites Stand-alone
    Other conditions: Refractory, Relapsed, B Cell Lymphoma, B Cell Leukemia
    View official trial listing →
  • Status unknown NCT NCT03910842

    Treatment of Children CD19+ Leukemia and Non-Hodgkin Lymphoma With CD19-TriCAR-T/SILK Cell Therapy

    Not yet reported Timmune Biotech Inc. 12 participants Est. completion 2022-10-15 1 site Stand-alone
    Other conditions: Non-Hodgkin Lymphoma of Intestine, Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT03913026

    UM171 Expanded Cord Blood In Patients With High-Risk Acute Leukemia/Myelodysplasia

    Not yet reported Ciusss de L'Est de l'Île de Montréal 30 participants Est. completion 2027-06 1 site Stand-alone
    Other conditions: High Risk Hematologic Malignancy, Cord Blood Transplant
    View official trial listing →
  • No Longer Available NCT NCT03914885

    Compassionate Use Re-Infusion of ATLCAR.CD30

    UNC Lineberger Comprehensive Cancer Center 1 site
    Other conditions: Hodgkin Lymphoma, Adult
    View official trial listing →
  • Completed NCT NCT03939026

    Safety and Efficacy of ALLO-501 Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell or Follicular Lymphoma

    Not yet reported Allogene Therapeutics 50 participants Est. completion 2025-01-28 7 sites Stand-alone
    Other conditions: Relapsed/Refractory Large B Cell Lymphoma, Relapsed/Refractory Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT03953599

    CD19-Synthetic T Cell Antigen Receptor(STAR)-T in B-cell Malignancies Patients

    Not yet reported Hebei Yanda Ludaopei Hospital 18 participants Est. completion 2021-12-31 1 site Stand-alone
    Other conditions: B Cell Malignancy
    View official trial listing →
  • Terminated NCT NCT03960060

    A Study of CCT301-59 CAR T Therapy in Adult Subjects With Recurrent or Refractory Solid Tumors

    Not yet reported Shanghai PerHum Therapeutics Co., Ltd. 9 participants Est. completion 2023-06-30 1 site Stand-alone
    Other conditions: Solid Tumor, Soft Tissue Sarcoma, Gastric Cancer, Pancreatic Cancer, Bladder Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT03967223

    Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors

    Not yet reported USWM CT, LLC 103 participants Est. completion 2028-07-31 38 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Withdrawn NCT NCT04029038

    Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center Est. completion 2022-11-16 1 site Stand-alone
    Other conditions: CD19 Positive, CD22 Positive, Minimal Residual Disease, Progressive Disease, Recurrent B Acute Lymphoblastic Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Non-Hodgkin Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Non-Hodgkin Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04037566

    CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

    Not yet reported Xijing Hospital 40 participants Est. completion 2024-08 1 site Stand-alone
    Other conditions: Leukemia Lymphocytic Acute (ALL) in Relapse, Leukemia Lymphocytic Acute (All) Refractory, Lymphoma, B-Cell, CD19 Positive
    View official trial listing →
  • Completed NCT NCT04103879

    US Study of UM171-Expanded CB in Patients With High Risk Leukemia/Myelodysplasia

    Not yet reported ExCellThera inc. 30 participants Est. completion 2026-02-28 3 sites Stand-alone
    Other conditions: High Risk Hematological Malignancy, Cord Blood Transplant
    View official trial listing →
  • Completed NCT NCT04121507

    ASTRAL- a Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy

    Not yet reported GWT-TUD GmbH 60 participants Est. completion 2023-02-02 13 sites
    Other conditions: Aggressive Non-hodgkin Lymphoma (aNHL), Lymphoma, B-Cell, Lymphoma, T-Cell
    View official trial listing →
  • Terminated NCT NCT04160195

    T Cells Expressing Fully-human Anti-CD19 and Anti-CD20 Chimeric Antigen Receptors for Treating B-cell Malignancies and Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) 2 participants Est. completion 2021-06-11 1 site
    Other conditions: Lymphoma, B-Cell, Lymphoma, Non-hodgkins, Chronic Lymphocytic Leukemia, B-Cell Chronic Lymphocytic Leukemia
    View official trial listing →
  • Status unknown NCT NCT04162119

    Safety and Efficiency Study of BCMA-PD1-CART Cells in Relapsed/Refractory Multiple Myeloma

    Not yet reported Chinese PLA General Hospital 30 participants Est. completion 2022-10-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Approved For Marketing NCT NCT04162756

    Study of Brexucabtagene Autoleucel (KTE-X19) for the Treatment of Individuals With Relapsed/Refractory B-Cell Malignancies

    Kite, A Gilead Company 9 sites
    Other conditions: Relapse/Refractory Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04163302

    Safety and Efficiency Study of CD19-PD1-CART Cell in Relapsed/Refractory B Cell Lymphoma

    Not yet reported Chinese PLA General Hospital 30 participants Est. completion 2022-07-01 1 site Stand-alone
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Completed NCT NCT04165967

    Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma

    Not yet reported University Hospital, Basel, Switzerland 9 participants Est. completion 2023-03-30 1 site Stand-alone
    Other conditions: Advanced Melanoma
    View official trial listing →
  • Active, not recruiting NCT NCT04167683

    Muscle Dysfunction in Patients With Hematological Diseases Referred to Stem Cell Transplant

    Rigshospitalet, Denmark 144 participants Est. completion 2026-11-01 1 site
    Other conditions: Hematologic Diseases, Chronic Myeloid Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia, Myelodysplastic Syndromes, Non Hodgkin Lymphoma, Stem Cell Transplant Complications, Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04181827

    A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 419 participants Est. completion 2027-03-31 88 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04250051

    Ivosidenib and Combination Chemotherapy for the Treatment of IDH1 Mutant Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported Northwestern University 2 participants Est. completion 2022-12-20 1 site Stand-alone
    Other conditions: Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Recurrent Myeloproliferative Neoplasm, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome, Newly Diagnosed Acute Myeloid Leukemia (AML), IDH1 Mutation Myeloid Neoplasms, Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Completed NCT NCT04260932

    CD19/CD20 Dual-CAR-T in B-cell Lymphoma Patients

    Not yet reported Hebei Yanda Ludaopei Hospital 12 participants Est. completion 2021-09-10 1 site Stand-alone
    Other conditions: B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT04260945

    CD19/CD20 Dual-CAR-T in B-cell Leukemia Patients

    Not yet reported Hebei Yanda Ludaopei Hospital 12 participants Est. completion 2022-02-10 1 site Stand-alone
    Other conditions: B-cell Leukemia
    View official trial listing →
  • Status unknown NCT NCT04264039

    Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

    Not yet reported Xinqiao Hospital of Chongqing 30 participants Est. completion 2022-04-01 1 site Stand-alone
    Other conditions: B-cell Acute Lymphoblastic Leukemia, B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT04269811

    Flu-Bu-Mel Conditioning Regimen for Myeloid Disease

    Not yet reported Shanghai Jiao Tong University School of Medicine 49 participants Est. completion 2023-06-30 2 sites Stand-alone
    Other conditions: Relapse Rate After Allo-HSCT
    View official trial listing →
  • Completed NCT NCT04325841

    Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children

    Not yet reported Beijing Boren Hospital 2 participants Est. completion 2024-04-03 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
    View official trial listing →
  • Status unknown NCT NCT04385641

    Study on the Safety and Effectiveness of UCB-NK Cell Infusion in the Treatment of Advanced Gastric Cancer and Gastroesophageal Cancer

    Not yet reported Shandong Golden Brick Biotechnology Co., Ltd. 18 participants Est. completion 2022-10-08 1 site Stand-alone
    Other conditions: Advanced Gastric Cancer, Gastroesophageal Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT04416984

    Safety and Efficacy of ALLO-501A Anti-CD19 Allogeneic CAR T Cells in Adults With Relapsed/Refractory Large B Cell Lymphoma, Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (ALPHA2)

    Not yet reported, Not yet reported Allogene Therapeutics 160 participants Est. completion 2029-05 29 sites Stand-alone
    Other conditions: Relapsed or Refractory Large B Cell Lymphoma, Relapsed or Refractory Chronic Lymphocytic Leukemia, Relapsed or Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT04432506

    Anakinra for the Reduction of CAR-T Toxicity in Patients With Relapsed or Refractory Large B-cell Lymphoma

    Not yet reported M.D. Anderson Cancer Center 22 participants Est. completion 2024-05-28 1 site Stand-alone
    Other conditions: Hematopoietic and Lymphoid Cell Neoplasm, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma, Recurrent Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT04473911

    Haplo Peripheral Blood Sct In GVHD Prevention

    Not yet reported Zachariah Michael DeFilipp 25 participants Est. completion 2024-08-19 1 site Stand-alone
    Other conditions: GVHD, AML, ALL, MDS, MPN, CMML, Hodgkin Lymphoma, Non Hodgkin Lymphoma, Blood Stem Cell Transplant Failure, Graft Vs Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorder, Chronic Myelomonocytic Leukemia, Chemosensitive Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT04526795

    Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia

    Not yet reported M.D. Anderson Cancer Center 19 participants Est. completion 2024-11-15 1 site Stand-alone
    Other conditions: Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent T-Cell Prolymphocytic Leukemia, Refractory Acute Biphenotypic Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory T-Cell Prolymphocytic Leukemia
    View official trial listing →
  • Suspended NCT NCT04539366

    Testing a New Immune Cell Therapy, GD2-Targeted Modified T-cells (GD2CART), in Children, Adolescents, and Young Adults With Relapsed/Refractory Osteosarcoma and Neuroblastoma, GD2-CAR PERSIST Trial

    Not yet reported National Cancer Institute (NCI) 73 participants Est. completion 2040-12-31 6 sites Stand-alone
    Obstructive sleep apnea Other conditions: Recurrent Childhood Neuroblastoma, Recurrent Neuroblastoma, Refractory Childhood Neuroblastoma, Refractory Neuroblastoma
    View official trial listing →
  • Status unknown NCT NCT04546893

    Safety and Efficacy Study of SL1904B CAR-T Cells for Relapsed or Refractory B-Cell Acute Lymphocyte Leukemia

    Not yet reported Hebei Senlang Biotechnology Inc., Ltd. 20 participants Est. completion 2022-12-01 2 sites Stand-alone
    Other conditions: B-ALL
    View official trial listing →
  • Status unknown NCT NCT04626765

    CAR-T for Children With Relapsed and Refractory Acute Lymphoblastic Leukemia

    Not yet reported Hebei Senlang Biotechnology Inc., Ltd. 50 participants Est. completion 2023-05-30 1 site Stand-alone
    Other conditions: Childhood Acute Lymphoblastic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04629729

    FT819 in Subjects With B-cell Malignancies

    Not yet reported Fate Therapeutics 54 participants Est. completion 2039-09-30 18 sites Stand-alone
    Other conditions: Lymphoma, B-Cell, Chronic Lymphocytic Leukemia, Precursor B-Cell Acute Lymphoblastic Leukemia
    View official trial listing →
  • Status unknown NCT NCT04632316

    A Trial to Evaluate the Safety and Efficacy of oNKord® in Subjects With Acute Myeloid Leukemia

    Not yet reported, Not yet reported Glycostem Therapeutics BV 33 participants Est. completion 2023-04 10 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT04633148

    Dose-escalating Trial With UniCAR02-T Cells and PSMA Target Module (TMpPSMA) in Patients With Progressive Disease After Standard Systemic Therapy in Cancers With Positive PSMA Marker

    Not yet reported AvenCell Europe GmbH 16 participants Est. completion 2024-03-28 4 sites Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Status unknown NCT NCT04637269

    Anti-BCMA CAR-T Cell Therapy for the R/R Multiple Myeloma

    Not yet reported Xinqiao Hospital of Chongqing 16 participants Est. completion 2023-11-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04639245

    Genetically Engineered Cells (MAGE-A1-specific T Cell Receptor-transduced Autologous T-cells) and Atezolizumab for the Treatment of Metastatic Triple Negative Breast Cancer, Urothelial Cancer, or Non-small Cell Lung Cancer

    Not yet reported, Not yet reported Fred Hutchinson Cancer Center 1 participants Est. completion 2022-08-16 1 site Stand-alone
    Other conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Lung Non-Small Cell Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Triple-Negative Breast Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Lung Cancer AJCC v8
    View official trial listing →
  • Status unknown NCT NCT04665076

    Multicenter Clinical Study on the Safety and Effectiveness of CAR-T in the Treatment of Relapsed/Refractory Plasma Cell Tumors

    Not yet reported Hebei Senlang Biotechnology Inc., Ltd. 60 participants Est. completion 2025-10-21 1 site Stand-alone
    Other conditions: Plasma Cell Tumors
    View official trial listing →
  • Suspended NCT NCT04697290

    CD19/CD20 Dual-CAR-T in B-cell Non-Hodgkin's Lymphoma Patients.

    Not yet reported Beijing Tsinghua Chang Gung Hospital 12 participants Est. completion 2023-06-10 1 site Stand-alone
    Other conditions: B-cell Non-Hodgkin's Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04713956

    G-CSF+DAC+BUCY vs G-CSF+DAC+BF Conditioning Regimen for RAEB-1,REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

    Not yet reported, Not yet reported Nanfang Hospital, Southern Medical University 242 participants Est. completion 2024-07-31 1 site Stand-alone
    Other conditions: Myelodysplastic Syndrome, Allogeneic Hematopoietic Stem Cell Transplantation, Conditioning
    View official trial listing →
  • Active, not recruiting NCT NCT04732845

    Human AntiCD19 Chimeric Antigen Receptor T Cells for Relapsed or Refractory Lymphoid Malignancies

    Not yet reported Benjamin Tomlinson 18 participants Est. completion 2039-12-01 1 site Stand-alone
    Other conditions: Non Hodgkin Lymphoma, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04756648

    Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma

    Not yet reported Zhejiang University 21 participants Est. completion 2026-06-01 1 site Stand-alone
    Other conditions: Advanced Hepatocellular Carcinoma
    View official trial listing →
  • Status unknown NCT NCT04766840

    Donor-derived CAR-T Cells in the Treatment of AML Patients

    Not yet reported Beijing Immunochina Medical Science & Technology Co., Ltd. 9 participants Est. completion 2023-12-01 1 site Stand-alone
    Other conditions: AML
    View official trial listing →
  • Active, not recruiting NCT NCT04787263

    CD19-CAR_Lenti T Cells in Pediatric Patients Affected by Relapsed/Refractory CD19+ ALL and DLBCL or PML

    Not yet reported, Not yet reported Bambino Gesù Hospital and Research Institute 32 participants Est. completion 2038-03-03 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Primary Mediastinal Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04823091

    Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

    Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 24 participants Est. completion 2024-04-07 1 site Stand-alone
    Other conditions: T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia, T Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04888442

    Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL

    Not yet reported Chongqing Precision Biotech Co., Ltd 18 participants Est. completion 2022-03-28 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, in Relapse, Refractory Acute Lymphoblastic Leukemia
    View official trial listing →
  • Withdrawn NCT NCT04893915

    Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS

    Not yet reported Washington University School of Medicine Est. completion 2024-12-31 Stand-alone
    Other conditions: Relapsed Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Active, not recruiting NCT NCT04898894

    Study of Selinexor and Venetoclax in Combination With Chemotherapy in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

    Not yet reported St. Jude Children's Research Hospital 37 participants Est. completion 2027-09 8 sites Stand-alone
    Other conditions: Acute Leukemia of Ambiguous Lineage in Relapse, Acute Myeloid Leukemia, in Relapse, Refractory Acute Leukemia of Ambiguous Lineage, Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Status unknown NCT NCT04933825

    A Study of ET-02 in Patients With Relapsed or Refractory B-cell Malignancy(NHL/ALL)

    Not yet reported EdiGene (GuangZhou) Inc. 18 participants Est. completion 2024-09-30 1 site Stand-alone
    Other conditions: Relapsed or Refractory B-cell Malignancy(NHL/ALL)
    View official trial listing →
  • Completed NCT NCT04965597

    Treosulfan-Based Conditioning Regimen Before a Blood or Bone Marrow Transplant for the Treatment of Bone Marrow Failure Diseases (BMT CTN 1904)

    Not yet reported Fred Hutchinson Cancer Center 40 participants Est. completion 2026-02-18 24 sites Stand-alone
    Other conditions: Bone Marrow Failure Syndrome, Congenital Amegakaryocytic Thrombocytopenia, Diamond-Blackfan Anemia, Hereditary Sideroblastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Shwachman-Diamond Syndrome, Hematologic Neoplasm With Germline GATA2 Mutation, Hematologic Neoplasm With Germline SAMD9 Mutation, Hematologic Neoplasm With Germline SAMD9L Mutation
    View official trial listing →
  • Withdrawn NCT NCT04982354

    Induction Therapy for Patients With FLT3 Mutated Acute Myeloid Leukemia

    Not yet reported, Not yet reported Guenther Koehne Est. completion 2032-08-01 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT04994808

    Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia

    Not yet reported Fred Hutchinson Cancer Center 23 participants Est. completion 2026-07-16 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Terminated NCT NCT05000450

    Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Allogene Therapeutics 6 participants Est. completion 2023-10-11 4 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05005299

    Venetoclax in Combination With Non-myeloablative Conditioning Allogeneic Haematopoietic Stem Cell Transplantation

    Not yet reported Melbourne Health 18 participants Est. completion 2026-03-31 1 site Stand-alone
    Other conditions: Leukemia, Myeloid, Acute, Leukemia, Lymphoblastic, Acute, L1, Leukemia, Lymphoblastic, Acute, L2, Myelodysplastic Syndromes, Non-hodgkin Lymphoma, Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05020015

    A Study of TAK-007 in Adults With Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)

    Not yet reported Takeda 27 participants Est. completion 2038-12-20 15 sites Stand-alone
    Other conditions: Relapsed or Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)
    View official trial listing →
  • Completed NCT NCT05022849

    A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

    Not yet reported Janssen Research & Development, LLC 15 participants Est. completion 2026-03-11 8 sites Stand-alone
    Other conditions: Prostatic Neoplasms
    View official trial listing →
  • Terminated NCT NCT05035407

    T Cell Receptor Gene Therapy Targeting KK-LC-1 for Gastric, Breast, Cervical, Lung and Other KK-LC-1 Positive Epithelial Cancers

    Not yet reported National Cancer Institute (NCI) 36 participants Est. completion 2025-07-16 1 site Stand-alone
    Other conditions: Kita-kyushu Lung Cancer Antigen 1, Human
    View official trial listing →
  • Active, not recruiting NCT NCT05088356

    Reduced Intensity Allogeneic HCT in Advanced Hematologic Malignancies w/T-Cell Depleted Graft

    Not yet reported Stanford University 66 participants Est. completion 2028-05 1 site Stand-alone
    Other conditions: Allogeneic Hematopoietic Cell Transplantation (HCT), Advanced Hematologic Malignancies, Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplastic Syndromes, Myeloproliferative Disorders
    View official trial listing →
  • Active, not recruiting NCT NCT05120271

    BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors

    Not yet reported, Not yet reported Sotio Biotech Inc. 7 participants Est. completion 2042-12 8 sites Stand-alone
    Obstructive sleep apnea Other conditions: Hepatocellular Carcinoma, Squamous Cell Carcinoma of the Lung, Merkel Cell Carcinoma
    View official trial listing →
  • Status unknown NCT NCT05122221

    CRTE7A2-01 TCR-T Cell for HPV-16 Positive Advanced Cervical, Anal, or Head and Neck Cancers

    Not yet reported Corregene Biotechnology Co., Ltd 12 participants Est. completion 2024-12 1 site Stand-alone
    Other conditions: Cervical Cancer, Anal Cancer, Head and Neck Cancers
    View official trial listing →
  • Active, not recruiting NCT NCT05139004

    90Y-DOTA-anti-CD25 Basiliximab, Fludarabine, Melphalan, and Total Marrow and Lymphoid Irradiation for the Treatment of High-Risk Acute Leukemia or Myelodysplastic Syndrome

    Not yet reported City of Hope Medical Center 7 participants Est. completion 2027-06-13 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05146739

    Highest Dose of Uproleselan in Combination With Fludarabine and Cytarabine for Patients With Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Mixed Phenotype Acute Leukemia Relapsed or Refractory That Expresses E-selectin Ligand on the Cell Membrane

    Not yet reported National Cancer Institute (NCI) 8 participants Est. completion 2027-05-09 19 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia Post Cytotoxic Therapy, Myelodysplastic Syndrome Post Cytotoxic Therapy, Myeloid Leukemia Associated With Down Syndrome, Recurrent Acute Myeloid Leukemia, Recurrent Mixed Phenotype Acute Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Mixed Phenotype Acute Leukemia, Refractory Myelodysplastic Syndrome
    View official trial listing →
  • Withdrawn NCT NCT05293509

    Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

    Not yet reported M.D. Anderson Cancer Center Est. completion 2023-09-18 1 site Stand-alone
    Other conditions: Stem Cell Transplantation
    View official trial listing →
  • Not yet recruiting NCT NCT05319249

    Natural Killer Cell Immunotherapy in Combination With PARP-inhibition in Acute Myeloid Leukemia

    Not yet reported, Not yet reported German Cancer Research Center 54 participants Est. completion 2028-06 Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT05358808

    ACHIEVE - Efficacy and Effectiveness of Adoptive Cellular tHerapy wIth Ex-Vivo Expanded Allogeneic γδ T-lymphocytes (TCB008) for Patients With Refractory or Relapsed Acute Myeloid Leukaemia (AML)

    Not yet reported TC Biopharm 16 participants Est. completion 2025-07-30 6 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Terminated NCT NCT05395052

    FT536 Monotherapy and in Combination With Monoclonal Antibodies in Advanced Solid Tumors

    Not yet reported Fate Therapeutics 5 participants Est. completion 2023-08-11 5 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Head and Neck Cancer, GastroEsophageal Cancer
    View official trial listing →
  • Terminated NCT NCT05397093

    ITIL-306 in Advanced Solid Tumors

    Not yet reported Instil Bio 1 participants Est. completion 2026-03-06 2 sites Stand-alone
    Other conditions: Epithelial Ovarian Cancer, Non-small Cell Lung Cancer, Renal Cell Carcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT05470283

    Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

    Not yet reported M.D. Anderson Cancer Center 21 participants Est. completion 2027-04-01 1 site Stand-alone
    Other conditions: Tumor, Metastatic Melanoma, Melanoma
    View official trial listing →
  • Status unknown NCT NCT05487651

    Allogeneic NK T-Cells Expressing CD19 Specific CAR in B-Cell Malignancies

    Not yet reported Athenex, Inc. 36 participants Est. completion 2024-12 3 sites Stand-alone
    Other conditions: NHL, Relapsed, Adult, B-cell Lymphoma, B-cell Leukemia, DLBCL - Diffuse Large B Cell Lymphoma, ALL, Adult B Cell, ALL, Childhood, CLL/SLL
    View official trial listing →
  • Completed NCT NCT05518357

    LILRB4 STAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported Hebei Yanda Ludaopei Hospital 2 participants Est. completion 2022-11-15 1 site Stand-alone
    Other conditions: Relapsed/Refractory Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT05534620

    Effect of Moderate Renal Impairment and Race/Ethnicity on Treosulfan Pharmacokinetics

    Not yet reported medac GmbH 20 participants Est. completion 2025-06-13 3 sites Stand-alone
    Other conditions: Acute Myeloid Leukaemia (AML), Myelodysplastic Syndrome (MDS), Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)
    View official trial listing →
  • Not yet recruiting NCT NCT05539768

    Study on the Safety and Efficacy of Autogenous Tumor Infiltrates Lymphocytes for the Treatment of Advanced Solid Tumor

    Not yet reported The Affiliated Hospital of Qingdao University 8 participants Est. completion 2027-03-31 Stand-alone
    Other conditions: Advanced Solid Tumor
    View official trial listing →
  • Completed NCT NCT05563545

    Anti-CD19 CAR-Engineered NK Cells in the Treatment of Relapsed/Refractory Acute Lymphoblastic Leukemia

    Not yet reported Shanghai Simnova Biotechnology Co.,Ltd. 2 participants Est. completion 2022-11-25 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05577000

    Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma

    Not yet reported Thomas Martin, MD 5 participants Est. completion 2038-08-31 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT05588440

    A Clinical Study of ONCT-808 in Subjects With Relapsed or Refractory B-Cell Malignancies

    Not yet reported, Not yet reported Oncternal Therapeutics, Inc 9 participants Est. completion 2024-09-12 4 sites Stand-alone
    Other conditions: Relapsed/Refractory Aggressive B-Cell Malignancies
    View official trial listing →
  • Active, not recruiting NCT NCT05600426

    A Trial Comparing Unrelated Donor BMT With IST for Pediatric and Young Adult Patients With Severe Aplastic Anemia (TransIT, BMT CTN 2202)

    Not yet reported Boston Children's Hospital 53 participants Est. completion 2029-12 52 sites
    Other conditions: Severe Aplastic Anemia
    View official trial listing →
  • Active, not recruiting NCT NCT05624554

    A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

    Not yet reported Merck Sharp & Dohme LLC 300 participants Est. completion 2031-03-17 97 sites
    Other conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT05634785

    CD30 CAR for CD30+ NSGCT

    Not yet reported UNC Lineberger Comprehensive Cancer Center 2 participants Est. completion 2025-12-18 1 site Stand-alone
    Other conditions: Germ Cell Tumor, Nonseminomatous Germ Cell Tumor
    View official trial listing →
  • Status unknown NCT NCT05651100

    Safety and Efficacy of Sequential CD19 and CD22 Targeted CAR-T Therapy for Relapsed/Refractory B Cell Lymphoma

    Not yet reported, Not yet reported Kecellitics Biotech Company Ltd 50 participants Est. completion 2025-12-10 1 site Stand-alone
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Completed NCT NCT05653271

    ACE1831 in Adult Subjects With Relapsed/ Refractory CD20-expressing B-cell Malignancies

    Not yet reported Acepodia Biotech, Inc. 16 participants Est. completion 2026-03-31 13 sites Stand-alone
    Other conditions: B-cell Lymphoma, Non Hodgkin Lymphoma, DLBCL, Primary Mediastinal Large B Cell Lymphoma, Marginal Zone Lymphoma, Follicular Lymphoma, Burkitt Lymphoma, High-grade B-cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT05665062

    Autologous CD19 CAR-T Cell Therapy (SYNCAR-001) + Orthogonal IL-2 (STK-009) in Subjects With CD19+ Hematologic Malignancies

    Not yet reported Synthekine 36 participants Est. completion 2041-11 4 sites Stand-alone
    Other conditions: CLL/SLL, NHL, Mantle Cell Lymphoma, Follicular Lymphoma, Large B-cell Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT05678205

    A Clinical Trial of the Safety and Anti-Tumor Activity of AB-201 in Subjects With Advanced HER2+ Solid Tumors

    Not yet reported, Not yet reported Artiva Biotherapeutics, Inc. Est. completion 2027-04 2 sites Stand-alone
    Other conditions: Breast Cancer, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma
    View official trial listing →
  • Status unknown NCT NCT05691153

    ThisCART19A for B-NHL Relapsed After Auto-CAR T

    Not yet reported The First Affiliated Hospital of Soochow University 20 participants Est. completion 2025-11-30 1 site Stand-alone
    Other conditions: CAR, B Cell Lymphoma, Relapsed Non-Hodgkin Lymphoma
    View official trial listing →
  • Status unknown NCT NCT05747157

    Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10- 19) in the Treatment of r/r B-ALL Clinical Research

    Not yet reported Anhui Provincial Hospital 18 participants Est. completion 2025-05-15 1 site Stand-alone
    Other conditions: B-cell Acute Lymphoblastic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05869955

    A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)

    Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 270 participants Est. completion 2028-08-29 46 sites Stand-alone
    Other conditions: Systemic Lupus Erythematosus, Idiopathic Inflammatory Myopathy, Systemic Sclerosis, Rheumatoid Arthritis
    View official trial listing →
  • Active, not recruiting NCT NCT05900401

    Delayed Tolerance Through Mixed Chimerism

    Not yet reported, Not yet reported Massachusetts General Hospital 20 participants Est. completion 2030-12 1 site Stand-alone
    Other conditions: Kidney Failure, Kidney Transplant; Complications, Chimera
    View official trial listing →
  • Status unknown NCT NCT05930314

    CNCT19 Cell Injection for Refractory Systemic Lupus Erythematosus

    Not yet reported Peking Union Medical College Hospital 12 participants Est. completion 2025-05-30 1 site Stand-alone
    Other conditions: Refractory Systemic Lupus Erythematosus, Lupus Nephritis, Immune Thrombocytopenia
    View official trial listing →
  • Withdrawn NCT NCT05950113

    CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Jonsson Comprehensive Cancer Center Est. completion 2028-03-28 1 site Stand-alone
    Other conditions: Recurrent Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06144385

    A Phase 1, Single-arm, Open-label, Dose-escalation Study of JWATM204 as T Cell-targeted Immunotherapy in the Treatment Amongst Subjects With Advanced Hepatocellular Carcinoma

    Not yet reported Shanghai Ming Ju Biotechnology Co., Ltd. 20 participants Est. completion 2024-12 1 site Stand-alone
    Other conditions: Liver Carcinoma, Hepatic Cell Carcinoma
    View official trial listing →
  • Withdrawn NCT NCT06190249

    Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma

    Not yet reported James Isaacs, MD Est. completion 2028-07 Stand-alone
    Other conditions: Stage IIIB Melanoma, Stage IIIC Melanoma, Stage IIID Melanoma
    View official trial listing →
  • Status unknown NCT NCT06206902

    F01 in the Treatment of Relapsed/Refractory Non-hodgkin's Lymphoma

    Not yet reported Shanghai Simnova Biotechnology Co.,Ltd. 55 participants Est. completion 2025-12 2 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT06220201

    A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)

    Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 120 participants Est. completion 2027-07-15 34 sites Stand-alone
    Other conditions: Multiple Sclerosis, Myasthenia Gravis
    View official trial listing →
  • Completed NCT NCT06236425

    TBio-4101 and Pembro wi/ or w/o Chemo in Recurrent/Metastatic HNSCC

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 7 participants Est. completion 2025-04-09 1 site Stand-alone
    Other conditions: Squamous Cell Carcinoma of Head and Neck, Metastatic Squamous Cell Carcinoma
    View official trial listing →
  • Status unknown NCT NCT06242249

    Anti-BCMA CAR-NK Therapy in Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Shahid Beheshti University of Medical Sciences 10 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: Multiple Myeloma, Refractory
    View official trial listing →
  • Terminated NCT NCT06295549

    Targeting CD19/CD20 Dual-targeted Cell in Patients With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 11 participants Est. completion 2025-08-22 3 sites Stand-alone
    Other conditions: Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT06314828

    A Tolerability, Safety and Efficacy Study of RJMty19 in Subjects With Relapsed or Refractory B-NHL

    Not yet reported Guangdong Ruishun Biotech Co., Ltd 30 participants Est. completion 2027-05-20 Stand-alone
    Other conditions: B-cell Non-Hodgkin's Lymphoma
    View official trial listing →
  • Status unknown NCT NCT06316076

    Safety and Efficacy Study of CD19-CAR-DNT Cells in Autoimmune Diseases

    Not yet reported RenJi Hospital 48 participants Est. completion 2026-06 1 site Stand-alone
    Other conditions: Systemic Lupus Erythematosus, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Idiopathic Inflammatory Myopathies, Systemic Sclerosis
    View official trial listing →
  • Status unknown NCT NCT06393335

    Safety and Efficacy of Metabolically Armed CD19 CAR-T Cells (Meta10-19) in the Treatment of Relapsed and/or Refractory CD19-positive B Cell Hematological Malignancies Clinical Research

    Not yet reported The Children's Hospital of Zhejiang University School of Medicine 36 participants Est. completion 2026-03-15 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Non-hodgkin Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT06464185

    A Prospective Clinical Study of CD3-CD20 Bisspecific Antibody Based Therapy Combined With CD19-CAR T Cells in the Treatment of Relapsed Refractory B-cell Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported Institute of Hematology & Blood Diseases Hospital, China 53 participants Est. completion 2027-04-30 1 site Stand-alone
    Other conditions: B-cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT06572631

    Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor

    Not yet reported City of Hope Medical Center Est. completion 2026-12-12 Stand-alone
    Other conditions: Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
    View official trial listing →
  • Not yet recruiting NCT NCT06641453

    CAR-T Cell Therapy Targeting GPC3 in Patients with Advanced GPC3-Positive Hepatocellular Carcinoma

    Not yet reported, Not yet reported Chinese PLA General Hospital 30 participants Est. completion 2028-11-15 1 site Stand-alone
    Other conditions: Hepatocellular Carcinoma (HCC)
    View official trial listing →
  • Suspended NCT NCT06663046

    Universal CAR-T Cells (REVO-UWD-00B) for Refractory and Relapsed Multiple Myeloma

    Not yet reported Wondercel Biotech (ShenZhen) 30 participants Est. completion 2029-12-30 1 site Stand-alone
    Other conditions: Multiple Myleoma, Refractory and Relapsed Multiple Myeloma
    View official trial listing →
  • Suspended NCT NCT06677710

    IDP-023 g-NK Cells Plus Ocrelizumab in Patients With Progressive Multiple Sclerosis

    Not yet reported Indapta Therapeutics, INC. 34 participants Est. completion 2028-12-31 5 sites Stand-alone
    Other conditions: Multiple Sclerosis, Primary Progressive Multiple Sclerosis (PPMS), Secondary Progressive Multiple Sclerosis (SPMS), Non-Active Secondary Progressive Multiple Sclerosis, Non-Active SPMS, Autoimmune Diseases of the Nervous System, Nervous System Diseases, Autoimmune Diseases, Demyelinating Diseases, Immune System Diseases, Demyelinating Autoimmune Diseases, Central Nervous System (CNS)
    View official trial listing →
  • Withdrawn NCT NCT06698744

    UF-KURE-BCMA CAR-T Cells in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported David Wald Est. completion 2028-09 1 site Stand-alone
    Other conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Multiple Myeloma, Refractory
    View official trial listing →
  • Completed NCT NCT06703346

    Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma

    Not yet reported USWM CT, LLC 82 participants Est. completion 2026-07-24 38 sites Stand-alone
    Other conditions: Neoplasms
    View official trial listing →
  • Active, not recruiting NCT NCT06752694

    Ruxolitinib Based GVHD Prophylaxis Regimen Before, During, and After Hematopoietic Cell Transplantation in Older Adult Patients With Acquired Aplastic Anemia

    Not yet reported Fred Hutchinson Cancer Center 1 participants Est. completion 2026-10-15 1 site Stand-alone
    Other conditions: Aplastic Anemia
    View official trial listing →
  • Not yet recruiting NCT NCT06879262

    Clinical Study of Novel TLR2-Containing CAR-T Cells Targeting CD19 and CD22 for Relapsed/Refractory B-ALL and NHL

    Not yet reported Tongji Hospital 60 participants Est. completion 2029-02-28 Stand-alone
    Other conditions: R/R NHL
    View official trial listing →
  • Terminated NCT NCT06912529

    Axicabtagene Ciloleucel CAR T-cells in Patients With Relapsed or Refractory Primary Mediastinal B-cell Lymphoma

    Not yet reported Universität Münster 1 participants Est. completion 2025-07-25 1 site Stand-alone
    Other conditions: B-cell Lymphoma Refractory, B-cell Lymphoma Recurrent
    View official trial listing →
  • Withdrawn NCT NCT06926985

    An Exploratory Clinical Study of Anti-CD19/BCMA Chimeric Antigen Receptor NK Cell Injection in the Treatment of IgA Nephropathy

    Not yet reported Jieyang People's Hospital Est. completion 2027-04-30 1 site Stand-alone
    Other conditions: IgA Nephropathy (IgAN)
    View official trial listing →
  • Active, not recruiting NCT NCT06961786

    TNFα and IL-2 Coding Oncolytic Adenovirus TILT-123 With Lymphocyte-depleting Chemotherapy and TILs in the Treatment of Melanoma

    Not yet reported TILT Biotherapeutics Ltd. 9 participants Est. completion 2027-04 1 site Stand-alone
    Other conditions: Metastatic Melanoma
    View official trial listing →
  • Not yet recruiting NCT NCT06986018

    Clinical Study on the Targeted CD19 Universal CAR-T Cell Injection (RD06-04) for the Treatment of IIM and AAV

    Not yet reported Peking University People's Hospital 12 participants Est. completion 2026-12-31 1 site Stand-alone
    Other conditions: Idiopathic Inflammatory Myopathies, ANCA-Associated Vasculitis
    View official trial listing →
  • Active, not recruiting NCT NCT07008378

    A Study to Evaluate the Safety, Tolerability, Cellular Kinetics, and Pharmacodynamics of P-CD19CD20-ALLO1 in Participants With Multiple Sclerosis

    Not yet reported Genentech, Inc. 60 participants Est. completion 2032-08-31 5 sites Stand-alone
    Other conditions: Multiple Sclerosis
    View official trial listing →
  • Not yet recruiting NCT NCT07052422

    VEN+DAC+Bu2Flu4 vs Bu2Flu5 Conditioning Regimen for Elderly Myeloid Malignancies Undergoing Allo-HSCT

    Not yet reported, Not yet reported Nanfang Hospital, Southern Medical University 160 participants Est. completion 2029-12-31 Stand-alone
    Other conditions: Older Patients, Myeloid Malignancies, Conditioning, Hematopoietic Stem Cell Transplantation (HSCT)
    View official trial listing →
  • Not yet recruiting NCT NCT07085156

    Reduced Intensity Conditioning for MDS

    Not yet reported Ruijin Hospital 45 participants Est. completion 2028-05-01 1 site Stand-alone
    Other conditions: MDS
    View official trial listing →
  • Active, not recruiting NCT NCT07139600

    Multi-omics Profiling of Patients With Aplastic Anemia Before and After CD7-CAR-T Therapy

    Xuzhou Medical University 5 participants Est. completion 2027-07-31 1 site
    Other conditions: Aplastic Anaemia, CAR-T, CD7 Positive
    View official trial listing →
  • Completed NCT NCT07155382

    Allogeneic HCT Using Conditioning Regimen of BuFluATG for AML CR1

    Asan Medical Center 98 participants Est. completion 2024-08-22 1 site
    Other conditions: Acute Myeloid Leukemia (AML)
    View official trial listing →
  • Not yet recruiting NCT NCT07166549

    Bispecific CAR T Cells for B-cell Malignancies (BaseCAR-01 Trial)

    Not yet reported University Hospital, Basel, Switzerland 12 participants Est. completion 2028-11 1 site Stand-alone
    Other conditions: B Cell Malignancies, B-cell Leukemia, B Cell Lymphoma, Bispecific Chimeric Antigen Receptor (CAR) T Cells, Relapsed or Refractory (r/r) B-cell Malignancies
    View official trial listing →
  • Enrolling by invitation NCT NCT07168486

    CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas

    Not yet reported University of Maryland, Baltimore 15 participants Est. completion 2028-07-01 1 site Stand-alone
    Other conditions: B-Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Primary Mediastinal Large B-cell Lymphoma (PMBCL), Follicular Lymphoma, Transformed Follicular Lymphoma (tFL), Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Richter Transformation, Marginal Zone Lymphoma
    View official trial listing →
  • Suspended NCT NCT07181720

    CD70-Targeted CAR-T Therapy in CD70-Positive Advanced Solid Tumors

    Not yet reported Chongqing Precision Biotech Co., Ltd 90 participants Est. completion 2028-05-31 1 site Stand-alone
    Other conditions: Renal Cell Carcinoma (RCC), Lung Cancer, Anaplastic Thyroid Carcinomas, Ovarian Cancer, Cervical Cancer, Thymic Carcinoma
    View official trial listing →
  • Enrolling by invitation NCT NCT07240857

    A Clinical Study Evaluating the Safety and Efficacy of Local Injection of ACT#001 Chimeric Antigen Receptor T Cells in the Treatment of Castration-Resistant Prostate Cancer

    Not yet reported Zhejiang University 18 participants Est. completion 2027-10-31 1 site Stand-alone
    Other conditions: Castration-Resistant Prostate Cancer (CRPC)
    View official trial listing →
  • Not yet recruiting NCT NCT07333820

    Clinical Study to Evaluate the Safety and Anti-Tumor Activity of AB-201

    Not yet reported Yonsei University 18 participants Est. completion 2028-03 1 site Stand-alone
    Other conditions: Malignant Neoplasm of Stomach, Unspecified
    View official trial listing →
  • Not yet recruiting NCT NCT07335094

    A Clinical Study of Humanized CD19 CAR-T Cells With TLR2 for the Treatment of Adult Patients With Naive B-Cell Acute Lymphoblastic Leukemia/Lymphoma Who Are Intolerant to Intensive Chemotherapy

    Not yet reported Zhujiang Hospital 60 participants Est. completion 2029-06-01 Stand-alone
    Other conditions: B Lymphoblastic Leukemia/Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07335562

    A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis

    Not yet reported Juno Therapeutics, Inc., a Bristol-Myers Squibb Company 92 participants Est. completion 2030-11-11 56 sites Stand-alone
    Other conditions: Systemic Sclerosis
    View official trial listing →
  • Not yet recruiting NCT NCT07342738

    TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

    Not yet reported Sun Yat-sen University 25 participants Est. completion 2029-02-01 1 site Stand-alone
    Other conditions: KRAS G12V, KRAS G12D, Solid Tumor
    View official trial listing →
  • Enrolling by invitation NCT NCT07539662

    Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS)

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 8 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: ALS (Amyotrophic Lateral Sclerosis)
    View official trial listing →
  • Not yet recruiting NCT NCT07593482

    Bendamustine Versus Fludarabine/Cyclophosphamide for Lymphodepletion in Chimeric Antigen Receptor T-cell Immunotherapy (CAR-T): a Randomized Trial.

    Not yet reported Swiss Cancer Institute 92 participants Est. completion 2030-03 9 sites
    Other conditions: B-cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT07604233

    Phase 1/2 FLAG-IDA, VEN and Asciminib in CML and Ph+ AML

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 30 participants Est. completion 2033-06-03 1 site Stand-alone
    Other conditions: Myeloid Leukemia
    View official trial listing →
  • Not yet recruiting NCT NCT07622862

    Exploratory Clinical Trial of DQ1001 in Relapsed or Refractory Multiple Myeloma (RRMM)

    Not yet reported Zhongshan Hospital (Xiamen), Fudan University 16 participants Est. completion 2028-08 Stand-alone
    Other conditions: Multiple Myeloma Refractory, Multiple Myeloma Progression
    View official trial listing →
  • Not yet recruiting NCT NCT07720180

    Study of Autologous, Metabolically Optimized, CD137+ Tumor-Infiltrating Lymphocytes Followed by Consolidative Oral Cyclophosphamide, Bevacizumab, and Pembrolizumab

    Not yet reported Medical University of South Carolina 20 participants Est. completion 2032-12-01 1 site Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Not yet recruiting NCT NCT07725406

    Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma

    Not yet reported Weill Medical College of Cornell University 32 participants Est. completion 2033-08-31 1 site Stand-alone
    Other conditions: Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL), Relapsed or Refractory Multiple Myeloma (MM)
    View official trial listing →
  • Not yet recruiting NCT NCT07758673

    Genetically Engineered Cells (BAFFR-CAR T Cells) for the Treatment of Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma

    Not yet reported City of Hope Medical Center 16 participants Est. completion 2028-07-26 2 sites Stand-alone
    Other conditions: Recurrent B Acute Lymphoblastic Leukemia, Recurrent B Lymphoblastic Lymphoma, Refractory B Acute Lymphoblastic Leukemia, Refractory B Lymphoblastic Lymphoma
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources

Also known as: Fludarabine Phosphate, Fludarabine, Fludara

Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.